University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2022

Effects of monovalent and divalent ions in factor xiii activation
and crosslinking.
Richard Laporca Lumata
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Chemistry Commons

Recommended Citation
Lumata, Richard Laporca, "Effects of monovalent and divalent ions in factor xiii activation and
crosslinking." (2022). Electronic Theses and Dissertations. Paper 3969.
https://doi.org/10.18297/etd/3969

This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

EFFECTS OF MONOVALENT AND DIVALENT IONS ON FACTOR XIII
ACTIVATION AND CROSSLINKING

By Richard L. Lumata
M.S., University of Louisville, 2022
B.S., Western Mindanao State University, 2006

A Thesis Submitted to the Faculty of the
College of Arts and Sciences of the University of Louisville
in Partial Fulfillment of the Requirements
for the Degree of

Master of Science in Chemistry

Department of Chemistry
University of Louisville
Louisville, Kentucky

August 2022

Copyright 2022 by Richard Laporca Lumata

All rights reserved

EFFECTS OF MONOVALENT AND DIVALENT IONS IN FACTOR XIII
ACTIVATION AND CROSSLINKING

By Richard Laporca Lumata
B.S., Western Mindanao State University, 2006
M.S., University of Louisville, 2022

A Thesis Approved on
June 22, 2022

by the following Thesis Committee:

Professor Muriel C. Maurer
Thesis Director

Professor Ying Li

Professor Andrew J. Wilson

Professor Michael A. Menze

ii

DEDICATION
This thesis is sincerely dedicated to my parents:
To my dearest Mother Mrs. Evelyn Laporca Lumata
and to my departed Father Mr. Jose delas Peñas Lumata

iii

ACKNOWLEDGEMENTS
It is with sincerest gratitude that I highly thank Dr. Muriel C. Maurer, my Advisor,
for guiding me persistently throughout my graduate studies here in University of Louisville
for the past 3 years. I have learned so much not only in Protein Chemistry but also my
overall skills as a Chemist. Thank you so much for the patience and understanding, Dr.
Maurer. To my thesis committee members, Dr. Ying Li, Dr. Michael Menze, and Dr.
Andrew Wilson, I thank you for your very helpful insights on how I can improve my thesis
manuscript. To my laboratory mates, I acknowledge Rameesa Darul Anne Syed
Mohammed for training me with all the assays I had performed, and other Laboratory mates
Francis Dean Ablan and Anoushka Bhat for their encouragement.
I also would like to thank my roommates Peter Armstrong, Faye Carvajal and Caleb
Calvary for also guiding me here in the graduate study life in UofL. To my Family, my
Mother Evelyn L. Lumata for the love and care. My siblings Lloyd Lumata, Analyn
Lumata, Edwin Lumata and Jenica Lumata for giving me inspiration. And to my friends,
relatives and classmates (Ryan Amilhussin, Clifford Tagactac, Meriam Lumio, Valerie
Napalcruz, Nadine Ardiente, Joyce Delima, Deborah Ogulu, Bernard Adjei, Mohan
Paudel, Sashil Chapagain, Harry Nambiar, Oskar Kharki, Touhid Islam, Dilmi
Waidyaratne, and Tonia Schansberg, Eric Schansberg, and Jenny Jokinen), thank you so
much for giving me the strength to finish this goal.

iv

ABSTRACT
EFFECTS OF MONOVALENT AND DIVALENT IONS IN FXIII
ACTIVATION AND CROSSLINKING
Richard L. Lumata
June 22, 2022

Factor XIII (FXIII) is an emerging target for treating blood clotting and
cardiovascular related diseases. FXIII can be activated non-proteolytically by the presence
of elevated Ca2+ levels (2-100 mM) or proteolytically by thrombin-cleavage of the
Activation Peptide along with low mM Ca2+. The studies herein utilized fluorescence to
examine how monovalent and divalent ions influence the transglutaminase activity and
conformation of FXIII. Monodansylcadaverine assays revealed that increasing ionic radius
(Cs+ > K+ > Na+ > Li+) and increasing ionic strength (XCl- levels and SO42- > Cl-) elevated
FXIII-A transglutaminase activity. Intrinsic fluorescence studies revealed that only cations
influenced FXIII conformation. For divalent salts, transglutaminase activity for MgSO4 is
~3-fold higher than MgCl2. Unlike transglutaminase 2, FXIII containing a mutation in the
Cab3 calcium binding site (G262V) could not exhibit an improvement in activity. A FXIII
Cab3 helix is proposed to be hindered which impacts non-proteolytically activated FXIII
more than proteolytically activated FXIII. Both cations and anions influence FXIII’s ability
to interact with substrates.
v

TABLE OF CONTENTS
ACKNOWLEDGEMENT………………………………………………………

iv

ABSTRACT…………………………………………………………………….

v

LIST OF TABLES ..................................................................................................... vii
LIST OF FIGURES……………………………………………………………...

x

CHAPTER
1. INTRODUCTION: FXIII IN BLOOD COAGULATION.………….….

1

2. EFFECTS OF IONS IN FXIII ACTIVATION VIA MONODANSYL
CADAVERINE INCORPORATION TO FIBRINOGEN αC (233-425)

17

3.

MONITORING INTRINSIC FLUORESCENCE OF HUMAN FXIII
ACTIVATED FORMS UNDER DIFFERENT MONOVALENT AND
DIVALENT SALTS ……………………………………………………

48

4. CHARACTERIZING HUMAN FXIII WILD TYPE vs G262V ……....

64

SUMMARY AND CONCLUSION ............................................................................82
REFERENCES ............................................................................................................ 84
APPENDICES............................................................................................................. 91
CURRICULUM VITAE ............................................................................................ 95

vi

LIST OF TABLES

1. Physiological concentrations of selected ions (in mM) in human
plasma and cells……………………………………………………………

18

2. Summary of periodic properties (ionic radii, ionic strengths, and
electronegativities) of selected monovalent and divalent salts…………….

28

3. Supporting Table S1. Curved fit and Bar Graph data (30 min reaction time) of
MDC incorporation assay (Chapter 2 and 4) ………………………………

91

4. Supporting Table S2. Percent change in terms maximum fluorescence intensity of
FXIII under different ionic and temperature conditions (Chapter 3) ………

vii

93

LIST OF FIGURES
1. Blood coagulation…………………………………………………….

2

2. Pathways in blood coagulation……………………………………….

3

3. Full fibrinogen structure………………………………………………

5

4. FXIII-A crosslinking via isopeptide bond formation using

fibrinogen substrates………………………………………………….

6

5. Sources of FXIII………………………………………………………

7

6. Activated vs inactivated forms of FXIII………………………………

9

7. Proteolytic and nonproteolytic activation of plasma FXIII A2B2

and cellular FXIII A2………………………………………………….

10

8. Transamidation mechanism of FXIII…………………………………

12

9. Transglutaminase 2 (TG2) activation mechanism……………………

15

10. Mechanism of isopeptide bond formation between reactive “Gln”

of Fbg αC (233-425) and “Lys” substrate MDC……………………...

27

11. MDC assay results of FXIII A2 with NaCl……………………………

29

12. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao with

NaCl vs FXIII-Ao with CaCl2…………………………………………...
13. MDC assay results of FXIII A2 with KCl…………………………….

30
32

14. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao with

KCl vs FXIII-Ao with NaCl………………………………………….

33

15. MDC assay results of FXIII-A2 with monovalent ion………………...

35

16. MDC assay results of FXIII A2 with LiCl, Li2SO4 and CsCl

37

17. Structures of organic salts Tetramethylammonium chloride (TMAC)

and Choline Chloride (ChCl)………………………………………...

38

18. MDC assay results of FXIII A2 with TMAC and ChCl……………...

39

19. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao with

TMAC, FXIII-Ao with ChCl and FXIII-Ao with LiCl……………….

40

20. MDC assay results of FXIII A2 with CaCl2, MgCl2 and MgSO4…….

41

21. Metal binding to amide of protein backbone mimic Butyramide……

45

22. FXIII active and inactive structure containing tryptophan residues…

49

viii

23. Emission spectra of FXIII A2 in borate buffer at room temperature

and 37oC conformation………………………………………………

53

24. Emission spectra comparison of NaCl vs CaCl2……………………...

54

25. Emission spectra of FXIII A2 with monovalent ions

under RT and 37oC……………………………………………………

56

26. Emission spectra of FXIII with 350 mM LiCl and Li2SO4

under RT and 37oC……………………………………………………

58

27. Emission spectra of FXIII with 350 mM MgCl2 and MgSO4 under

RT and 37oC………………………………………………………….

60

28. Conformational changes of FXIII and TG2 upon activation…………

64

29. Sequence alignment of FXIII and TG2 showing G262 of FXIII

and V224 of TG2……………………………………………………...

65

30. A pGEX-6P-1 plasmid DNA map…………………………………….

67

31. Crystal structure of FXIII-A showing the AP segments and

SDS PAGE of FXIII AP-cleavage by thrombin………………………

72

32. MDC assay result of FXIII WT vs FXIII G262V…………………….

74

33. Rate constant and Plateau formation of FXIII WT and mutant……....

75

34. FXIII-A Calcium binding site 3 (PDB 4KTY) and TG2

major calcium binding region (FXIII Cab3 equivalent) ……………...

77

35. FXIII A2 spatial views showing the residues in Cab1

(sky blue), Cab2 (pink) and Cab3 (green). …………………………...

79

36. Site directed mutagenesis purification results

for FXIII-A G262V generation………………………………………...
37. Free Tryptophan fluorescence with cations …………………………….

ix

90
92

CHAPTER I
FACTOR XIII (FXIII) IN BLOOD COAGULATION

Hemostasis: Introduction to blood coagulation
When a trauma injury occurs that affects a blood vessel (Fig. 1A), our normal
body’s response is to promote hemostasis. Upon vascular endothelium damage, collagen
fibrils along with von Willbrand factor (vWF) are exposed at the vessel wall (1). The vWF
links platelets to collagen via specific receptors in the platelet membrane known as Integrin
α2β1 and GPVI (2,3). At this stage, the platelets are activated from their resting state by
changing their shape into dendridic or pseudopodia forms (4). The activated platelets
subsequently release prothrombotic molecules such as Adenosine diphosphate (ADP).
These ADP biomolecules bind to specific receptor in platelets promoting recruitment of
more activated platelets (5). Platelets become crosslinked with each other in the presence
of a mediator known as thromboxane. This platelet aggregate now forms the so-called
platelet plug and triggers vasoconstriction that seals off the injury (Fig. 1B) (6). Platelet
activation also simultaneously promotes the activation of the extrinsic and intrinsic
pathways in the blood coagulation cascade (7) (Fig. 2) that will promote the last stage of
the cascade which is the clot formation. Other clot components include platelets that initiate
the vasoconstriction, red blood cells entrapped in a clot that regulate clot size (8), α2antiplasmin that acts as an inhibitor of plasmin (9), and fibronectin which is involved in
tissue repair (10), etc. (Fig. 1C).
1

Figure 1. Blood coagulation. A) shows how clot
formation occurs at the broken blood vessel B) red
blood cell retention and platelets plug formation
cause vasoconstriction C) clot formation. (Created
with BioRender)

The extrinsic and intrinsic pathways are interconnected to initiate the activation of
clotting factors. In the classical model of blood coagulation (Fig. 2A) (11), TF initiates in
the extrinsic pathway activates coagulation FVII, FIX and eventually generation of FX to
activate FII (thrombin) (12,13). Meanwhile, in the intrinsic pathway, several players are
involved (Prekallikerin, Kallikerin, FIX, FXII, FXI). Both the intrinsic and extrinsic
pathways merge in a common pathway known as the tenase complex. This complex then
generates thrombin to promote soft and hard clot formation where fibrinogen and FXIII
come in. The mechanism of this classical concept can be well-understood in the cell-based
model of blood coagulation (14,15).
In the cell-based model (Fig. 2B), upon tissue damage, tissue factor (TF), a cellbound transmembrane glycoprotein, triggers the activation of the extrinsic pathway and
subsequently the intrinsic pathway (Fig. 2B). There are three basic steps in the cell-based
model in a step-by-step fashion: (1) Initiation, (2) Amplification, and (3) Propagation
(14,16).

2

A

B Cell-based model of blood coagulation

Figure 2. A) Blood coagulation cascade: The extrinsic and intrinsic pathway. FXIII plays role
at the end stage of the cascade activated by thrombin and calcium which eventually facilitates
isopeptide bond formation of fibrin to form a stable clot (hard clot). Modified cascade based on
Adams et al 2009 coagulation cascade. B) Modified Initiation, Amplification and Propagation
phases of the cascade from Bittar et al 2015.

In the “Initiation Phase” (Step 1), TF forms a complex with FVIIa (TF:FVIIa) that
functions to activate zymogen FIX and FX to its active forms abbreviated as FIXa and FXa,
3

respectively (13,17). The generated FXa activates prothrombin (II) to thrombin (IIa). In
this step, only a small amount of IIa is produced (Fig. 2A) (18). This thrombin generation
from the initiation phase now plays a crucial role in the “amplification phase” (Step 2).
Platelet activation primarily occurs in the amplification phase that triggers activation of
several other coagulation factors not involved in the initiation phase (19). Thrombin, in the
presence of Na+, then facilitates the dissociation of FVIII from its cofactor, von Willebrand
factor to become FVIIIa and it also further activates FIX to FIXa. In this event, FIXa forms
a complex with FVIIIa (FIXa:FVIIIa), known as the intrinsic tenase complex (13). At the
same time, the FIXa forms a complex with FVa known as prothrombinase complex
(FIXa:FVa) that generates higher rate of thrombin formation. The presence of calcium ions
generates a positive feedback loop which rapidly catalyzes the conversion of II to IIa. The
amplification phase can activate thrombin 50 to 100-fold, much higher than the thrombin
generated in the initiation phase. At this phase, thrombin also binds with the platelet Gplbα
receptor that further increases interactions with other components of the plasma membrane
such as the protease-activated receptor 1 (PAR-1) (20,21).
Colocalization of the tenase and prothrombinase complexes in the presence of
calcium further enhances their efficiencies to generate more thrombin (22). This formation
of huge amounts of thrombin is also known as “the thrombin burst” that allows formation
of a much more stable clot. Finally, the third stage (Fig. 2C) emphasizes the “Propagation
phase” (Step 3) which allows for continuous thrombin generation and clot formation (16).
This final phase depends on the rate of platelet recruitment at the site of the injury which
necessitates optimal thrombin generation for the activation of FXIII and fibrinogen (23).
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Figure 3. Full fibrinogen structure. Fibrinogen is a dimer of trimers containing α helical coiled
coil (Aα, Bβ, γ), D, E, and αC regions.

Fibrinogen is a glycosylated protein (340kDa) containing nonidentical polypeptides
namely, Aα, Bβ, and γ linked with disulfide bonds. It is also comprised of three regions,
the central region (2 identical terminal D domains), the central E domain, and the αC region
(Fig. 3)(24,25). The fibrinogen (Fbg) αC domain (221-610) is where most of the
crosslinking takes place (26), and the Fbg (233-425) region contains three reactive
glutamines (Q237, Q328, and Q366) (27).
Fibrinogen is converted to fibrin when the N-terminal fibrinopeptides A and B of
the Aα and Bβ chains (Fig 4.) are cleaved off by thrombin (IIa) forming soluble fibrin. This
cleavage leads to the exposure of α and β knobs that are subsequently inserted into γC and
β holes of the D region to form protofibrils. Continuous aggregation of these protofibrils
results in the formation of a fibrin mesh also known as a soft clot (28-30).
Transglutaminase FXIII then comes in to make a more stable clot.

5

Figure 4. FXIII-A crosslinking via
isopeptide bond formation using
fibrinogen
substrates.
Step
(1)
Fibrinopeptide cleavage, Step (2)
Formation of fibrin, Step (3) formation
of soft clot ad, Step (4) hard clot
(crosslinked fibrin). Created with
BioRender.

Fibrin stabilizing factor (FXIII)
FXIII A2 is distributed both extracellularly (31) and intracellularly (32).
Coagulation FXIII A2 is expressed mainly in the cytosol of megakaryocytes which are cells
in the bone marrow that are also responsible for synthesizing platelets. The FXIII A2
derived from platelets contains a concentration that ranges from 46-82 fg/platelet (33).
Moreover, FXIII-A in platelet cytoplasm is 100-150x higher in concentration than FXIII
found in plasma. Other origins of FXIII A2 include the cytosol of monocytes, osteoblasts,
osteoclasts, and macrophages as shown in Fig. 5 (34-36). There are three ways that FXIII
A2 can be activated: FXIII from plasma undergoes proteolytic activation by thrombin at
low mM Ca2+, FXIII A2 to FXIII-Ao at low calcium in cells, and FXIIIA2 to FXIII-Ao at
high mM calcium in bones.
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Figure 5. Sources of FXIII. Bone marrow specifically the megakaryotes synthesize the bulk of
FXIII via platelet. and distributed intracellularly and extracellularly. Other sources come from
monocytes, macrophages, osteoclast, and osteoblast. (Created with BioRender)

For over a century, FXIII has been a target for medical and pharmacological
research due to its multifunctional roles in hemostasis, bone development (37),
angiogenesis, wound healing (38), signaling processes (39), and several intracellular
functions (36). Furthermore, congenital FXIII deficiency can lead to life-threatening
conditions: intracranial hemorrhages, miscarriage, and umbilical cord bleeding (40). The
main function of this type of transglutaminase (EC 2.3.2.13) is to catalyze the crosslinking
of protein substrates via isopeptide bond formation between the side chains of glutamine
and lysine residues (41).
Plasmatic FXIII circulates as a heterotetrameric (FXIII A2B2) protein complex
whereas cellular FXIII exists as a homodimer FXIII A2 (Fig. 7). The megakaryocytes are
the major source of FXIII A2. The liver synthesizes FXIII B2 and this regulatory protein
7

circulates in excess in plasma and binds with FXIII A2 to form FXIII A2B2 (42). The FXIII
B2 subunit serves as a protective group to prevent FXIII A2 from undergoing premature
activation. Furthermore, FXIII B2 of FXIII A2B2 binds to fibrinogen specifically at the Fbg
γ390-396 segment. Only 1% of the total FXIII A2 circulates in plasma with the remainder
proposed to bind to FXIII B2 (33). FXIII A2B2 circulates in plasma with an average
concentration of 22 mg/L and a half-life of 12 days (43). Besides crosslinking fibrin chains,
plasma FXIII A2B2 is also responsible for red blood cell retention within the clot network
(44,45).
Although FXIII and the rest of the transglutaminases are calcium-dependent, they
lack the EF hand motif which is a type of helix-loop-helix structure with a high binding
affinity for calcium (46,47). In plasma, FXIII A2 associates noncovalently with the
circulating FXIII B2 forming the heterotetramer FXIII A2B2. Polgar et al 1990 introduced
FXIII B2 into FXIII A2 activation with constant calcium concentration and found out that
the resultant transglutaminase decreased as a function of increasing FXIII B2 concentration.
These results helped confirm that B2 subunits interact with the FXIII A2 subunits hindering
premature FXIII activation (48). The two A subunits (83kDa) have the catalytic functions
whereas the two beta subunits, FXIII B2 (80kDa) serve as the carrier or regulatory group.
Each B subunit consists of 10 sushi domains that are spatially folded (36,49).
Intracellular FXIII A2 is activated to FXIII-Ao through nonproteolytic activation in
the presence of higher mM calcium concentration. This activated form FXIII-A is a 731residue polypeptide that contains five structural domains, namely: Activation Peptide
(Ser1-Arg37) which is part of the N terminal domain, two β-barrel domains β-barrel 1
(Ser516-Thr628) and β-barrel 2 (Il629-Met731), β sandwich domain (Gly38-Phe184), and
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one catalytic core domain (Asn185-Arg515) (36) as shown in Fig. 6. The catalytic core
domain contains the catalytic triad Cys314, His373, and Asp396 (50) whereas the role of
the Trp279 residue is to stabilize the oxyanion intermediate (36,51).

Figure 6) Activated vs inactivated forms of FXIII. A) FXIII A2 zymogen (PDB ID IF13) and B)
FXIII A Ca-Activated + 6-Diazo-5-oxonorleucinyl -inhibitor (PDB ID 4KYT). In the active state
FXIII A, only the β barrel (blue and yellow) domains changed position drastically but the catalytic
core (red) and β sandwich domain remain unchanged upon binding with calcium (sky blue). The
activation peptide (pink) appears as a disordered polypeptide.

The research group of Stieler and collaborators published the first high resolution
(1.98 Å) crystal structure of non-proteolytically activated FXIII-Ao (PDB 4KYT) in
complex with an irreversible inhibitor ZED1301 (Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-TrpPro-OH) containing an electrophilic Michael acceptor (52). Their results revealed that
binding of the inhibitor with monomeric FXIII-A (activated with 40 mM CaCl2) creates a
large conformational rearrangement to FXIII, and the β barrel domains swing aside upward
at a 90o angle to expose the catalytic core. Although there is large movement for the two
FXIII β barrel domains, they still conserve their overall fold. Studies performed by the
Philippou and Ariens groups demonstrated the significance of the two β barrel domains.
Their results showed that removal of β-barrel 2 led to total loss of FXIII activity and that
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truncations of both β barrels led to a 30% loss of activity. In addition, the β barrel 2 serves
to protect the cysteine in its active site in the zymogen form of FXIII whereas β barrel 1 is
needed to expose the active site during activation of FXIII (53). No conformational
rearrangement and changes to the β sandwich domain occur during the activation. These
results signify that the presence of β barrel domains plays a critical role in modulation of
the FXIII catalytic activity.
Activated FXIII-A crosslinks fibrin(ogen)’s glutamine (Q) and lysine (K)
substrates through isopeptide bond formation (γ-glutamyl-ε-lysyl amide bond) that
increases clot stability which now can be called a hard clot (Fig 4a). This fibrin stabilizing
factor plays essential roles in the crosslinking of protein substrates such as fibrin(ogen) to
form a mesh-like structure (54,55).
Cellular vs Plasma FXIII
Intracellularly, FXIII exists as a proenzyme homodimer, FXIII A2 (Fig. 7). The plasmatic
FXIII A2B2 is proteolytically activated whereas the intracellular FXIII A2 is

Figure 7.) Proteolytic and nonproteolytic activation of plasma FXIII A2B2and cellular FXIII
A2. The FXIII A2B2 undergoes cleavage of fibrinopeptide A and B via IIa (A) in the presence
of low Ca2+ FXIII B2 is released forming FXIII-A* (B). C) Cellular FXIII A2 forms FXIII-A*
at low Ca2+ and thrombin and FXIII A2B2 can also be nonproteolytically activated in the
presence of high Ca2+ (D).
10

nonproteolytically activated (Fig 7). Proteolytic activation of FXIII A2B2 occurs as a
multistage process. The first step involves the cleavage of the activation peptide (AP)
located at the N-terminus of the A subunit of FXIII with thrombin hydrolyzing the Arg37Gly38 peptide bond which leads to the formation of FXIII A'2B2 (56). The AP of FXIII
blocks access to the FXIII active site (57) and stabilizes the FXIII A2 dimer unit (58).
Calcium-assisted conformational rearrangement then occurs disrupting the
noncovalent interactions of the A and B subunits forming two homodimers (FXIII A'2 and
FXIII B2). With further calcium binding, the FXIII A2 promotes conformational changes
leading to the dissociation of the A subunits into FXIII-A monomers that exhibit
transglutaminase activities (59-61). Both plasma and cellular FXIII become a monomer
FXIII-A in its active state (60,62) as shown in Fig 7.
Anokhin et al. performed FXIII dissociation and activity assay with different
calcium concentrations (4-100 mM CaCl2). Results from the AUC studies demonstrated
that the monomeric form of FXIII increases as calcium concentration also increases (60).
A spectrophotometric assay with FXIII A2 activated nonproteolytically, FXIII-Ao, revealed
that transglutaminase activity also increases as a function of increasing calcium
concentration (61). Other ions were also previously tested for FXIII activation, such as the
monovalent ion sodium chloride (48,60,63).

Transamidation mechanism of FXIII
In the catalytic core domain of FXIII-Ao (PDB 4KYT), three calcium binding sites
were observed. The calcium binding (Cab) sites contain the following residues: Cab1 (Glu
485, Glu 490, Ala 457, and Asp 436), Cab2 (Asp 349, Asp 351, Asp 343, Asn 347, and
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Gln 459), and Cab3 (Asp 270 Asp 271, Ala 264, Lys269, and Asn 267) (52). Upon calcium
binding to site 1, α helices at Cab2 shift slightly and promote rotational movement of the
three stranded β sheet by the loop containing Asp 367 coordinating with Asp 351. These
movements cause the formation of the catalytic diad involving residues His 342 and Glu
401 needed for FXIII activity. The Cab3 contains the residues involved for Lysine (K) substrate binding region such as Lys 269. A loop in this region is also rearranged upon
calcium binding (51).

Figure 8. Transamidation mechanism of FXIII. Modified FXIII transamidation mechanism
as proposed by Imhof et al 2020.

FXIII contains an active site that contains a cysteine-like proteinase (64). The active
site consists of a catalytic triad (Cys314, His373, and Asp396) and a catalytic diad (His342
and Glu401) (52,57). In the general transamidation of fibrin substrates, one fibrin monomer
12

serves as a glutamine donor and another fibrin becomes a lysine donor to form an
isopeptide bond (65). In the first step of the reaction, the cysteine residue Cys314 of FXIIIA must be deprotonated via a general base, His373, making Cys314 a stronger nucleophile
(Fig. 8). The amide nitrogen of Cys314 is then protonated via proton transfer from the
protonated His373 (Step 1 -2) which occurs only if there is a cysteine-thiolate protonated
ion pair (51). Case and Stein proposed that there exists a neutral catalytic diad of Cys314His373 ion pair and the thiolate of Cys makes a nucleophilic attack in the rate-limiting step
(66). This was confirmed by their potential energies between Cys314 and His373 using
QM/MD calculations where the protonated form of Cys314 (54.7 kj/mol) obtained a
significantly much higher energy than the protonated His (36.1 kj/mol) (51). Hence, the
protonated ion-pair form of His has a much higher stability than the protonated Cys ionpair form. In step 2 of the mechanism, the imidazolium thiolate of Cys314 makes a
nucleophilic attack to the carboxyamide of the acyl donor, Glutamine. This attack leads to
the formation of a tetrahedral intermediate followed by release of the ammonia by a general
acid (imidazolium) to form the acyl-enzyme. This acyl enzyme can undergo two different
reactions depending on the type of the acyl, acceptor: H2O or Lysine containing protein or
peptide. In the presence of a Lysine-containing substrate, the imidazole group of Cys314
now functions as a general base making a nucleophilic attack to the thioester of Lysine
leading to deprotonation of the neutral lysine substrate forming a tetrahedral intermediate
(Step 3). Subsequently, decomposition of this intermediate releases the thiolate and forms
the transamidation product via isopeptide bond formation and regenerates a free,
catalytically active FXIII A (Step 4). However, in the absence of the Lysine substrate, H2O
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becomes a substrate of the acyl enzyme and promotes the hydrolysis of the glutamine
residue into glutamic acid (51).

Transglutaminase 2
Another type of transglutaminase that is closely related to FXIII is
Transglutaminase 2 (TG2) which is a multifunctional protein involved in post translational
modification, crosslinking of protein substrates, neurodegenerative disease, GTP
hydrolysis, scaffold activity, and a wide spectrum of other biological activities. Due to
these various functions, it plays important roles in wound healing, angiogenesis, apoptosis,
celiac disease, and several other cellular processes. Structurally, both TG2 and FXIII share
common domains including a catalytic domain, two C-terminal β barrel domains, and the
N terminal β sandwich domain. An exception is that activation peptides are absent in TG2.
Unlike FXIII which is activated by thrombin and/or calcium, TG2 is allosterically regulated
by calcium and GTP (Fig. 9) under fluctuating physiological conditions. In a recently
published paper, Arek et al. 2021 demonstrated how extracellular TG2 forms a molecular
redox reaction gate capable of activating or deactivating the protein (67). At high calcium
concentration, initial binding of Ca2+ to a high affinity calcium binding site protects TG2
from oxidative deactivation and helps promote calcium binding to a weaker binding site
developing an allosteric effect to activate TG2 (Fig. 9). Overall, Ca2+ positively regulates
TG2 whereas nucleotides such as GTP, GDP or ATP negatively regulate TG2 (68).
Similar to FXIII, TG2 also forms an open conformation upon activation (Fig. 8C).
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Figure 9. a) Transglutaminase 2 (TG2) activation mechanism. – Modified
mechanism based on Khosla et al 2021 (J. Am. Chem. Soc. 2021, 143, 10537-10540).
Created with BioRender.
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Overall Goal of the Study
The primary goal of this MS Thesis study was to examine the transglutaminase activity of
recombinant human wild type FXIII under different ionic concentrations and to probe the
conformational rearrangements to FXIII that may be occurring in these environments.
Besides the commonly used Ca2+ and Na+, the ions Li+, K+, Cs+ and Mg2+ were studied. In
an additional project, a TG2 mutation (G262V) located near Cab3 were introduced into
comparable positions of FXIII-A2. Impacts on FXIII-A2 activation and subsequent
crosslinking abilities were examined. Influences on Cab3 and the lysine binding surface
could be used to tune the properties of FXIII.
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CHAPTER II
EFFECTS OF IONS IN FXIII ACTIVATION VIA MONODANSYL CADAVERINE
INCORPORATION TO FIBRINOGEN αC (233-425)
Introduction

Fibrin stabilizing factor or FXIII is a calcium-dependent transglutaminase where
calcium serves as a cofactor regardless of the FXIII source, in plasma as FXIII A2B2
(heterotetramer) or in cells as FXIII A2 (dimer). FXIII contains three calcium binding sites
within the catalytic core domain (52). Cellular FXIII A2 was selected as the target
transglutaminase in the present study. Proteolytic activation of FXIII A2 requires low mM
Ca2+ and thrombin (IIa) cleaves the AP fragment to become FXIII-A* (69) whereas
nonproteolytic activation is promoted in a high mM Ca2+ (70) environment to become
FXIII-Ao (61). For this project, the focus was on cellular FXIII A2 and how divalent and
monovalent ions contribute to generating FXIII-Ao that exhibits transglutaminase activity.
Physiologically, both monovalent and divalent ions are present both extracellularly
and intracellularly. Table 1 shows a summary of cations and anions present in human
plasma and cells with their corresponding concentrations. In plasma, Na+ (150 mM) is the
chief cation (71), on the contrary, in the cytoplasm of cells, K+ (150 mM) dominates with
a concentration about ~30 fold higher than the Na+ (72,73). These monovalent cations (Na+
and K+) were proposed to help activate FXIII in the presence of low Ca2+, but no data were
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available to compare whether K+ exhibited similar or higher transglutaminase activity as
compared to Na+ (48). Previous studies suggested that increased Na+ concentration helped
increase platelet aggregation (74) whereas KCl supplementation decreased platelet
reactivity (71).
Table 1. Physiological concentrations of selected ions (in mM) in human plasma and cells
Ionic sources
Intracellular
(cytosolic)
Extracellular
(Plasma)

Monovalent cation
Na+
K+

10-35(75)

140-150(72,76)

135-145(75)

3.5-5(72,76)

Divalent cation
Mg2+
Ca2+

17-20(73,77,78)
1.21.4(73,77,78)

~ .0001(79)
2.-2.6(81,82)

Cl5(80)
120(80)

Anion
2SO4
Not known
0.5(83),
1-2 (84)

Extracellular calcium in plasma is much higher in concentration than the
intracellular Ca2+ in cells (82). Moreover, Mg2+ concentration in cells exceeds Mg2+ in
plasma (73,77,78). Upon platelet activation, calcium levels in their cytosol are increased
via calcium channels in the endoplasmic reticulum thereby elevating Ca2+ to
supraphysiological levels. The Cl- concentration in plasma is about ~20 fold higher than it
is in the cytoplasm of cells. Other salts (LiCl, CsCl, ChCl and TMAC) were also
investigated. Li+ is a popular drug used for treatment in bipolar disorder whereas CsCl is a
supplement for cancer treatment. In addition, LiCl supplementation has been found to
increase platelet count and aggregation (85-87).
Two organic salts were also examined. Choline chloride (ChCl) was used
previously as a cationic molecule to demonstrate that thrombin (88) and FXa (89) have
distinct Na+ binding sites. Tertramethylammonium chloride (TMAC) is a smaller organic
cation that has been used as a molecular enhancer for isothermal exponential amplification
reactions and other biochemical assays (90).
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The current study focused on investigating the effect of selected monovalent and
divalent ions on nonproteolytic activation of recombinant cellular FXIII A2. Overall, the
paramount goal of this study was to examine for changes in FXIII-catalyzed crosslinking
of fluorescent monodansylcadaverine (MDC), a lysine mimic (91), into reactive glutamine
of Fibrinogen αC (233-425). Fluorescent intensity (FLR) generated for crosslinking
product as a function of ion concentration and reaction time provided a measure of FXIII
transglutaminase activity.

Materials
Recombinant FXIII zymogen (FXIII A2) was kindly provided by the late Dr. Paul
Bishop (Zymogenetics, Seattle, WA, USA). Recombinant human thrombin (rhIIa) stocks
were procured from Dr. E. Di Cera and Ms L. Pelc (St. Louis University, St. Louis, MO,
USA). N,N-dimethylated β-Casein from bovine milk and the lysine mimic
monodansylcadaverine (MDC) were both purchased from Millipore Sigma (St. Louis, MO,
USA). The crosslinking agent for gel electrophoresis, 30% Acrylamide/Bis solution, and
the dual-color molecular weight standards were purchased from Bio-Rad Laboratories, Inc.
(Richmond, CA, USA). The catalyst TEMED (N,N,N,N-Tetramethylethylenediamine)
(MP Biomedicals, Solon OH, USA) and the protein denaturant SDS (sodium dodecyl
sulfate) were purchased from VWR Life Science, Ohio, USA. The monovalent ions NaCl
and Li2SO4 were purchased from Fisher chemical (Fair Lawn, NJ, USA) whereas LiCl,
KCl, CsCl, MgCl2, and MgSO4 were from Sigma (St. Louis, MO, USA).
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Methods
Expression and Purification of Fibrinogen αC WT (233 – 425)
Fibrinogen αC (233 – 425) is part of the C terminal region of the Fbg αC. This αC
region contains three reactive glutamines (Q237, Q328, and Q366) utilized by FXIII to
form isopeptide bonds with lysine substrates (92-94). The Fbg αC region also has a FXIII
binding site involving αC (389-403). Stocks of Fbg αC (233 – 425) fragment were
expressed and purified using the steps described below:

Recombinant protein expression
The PGEX-6P-1 plasmid containing complementary DNA for Gluthatione Stransferase (GST)-tagged Fbg αC fragment (233-425) was generously provided by the
Ariens and Philippou Labs of the University of Leeds, UK. This plasmid was transformed
into E. coli BL21 cells. Sterilized ZYP.08G medium (non-inducing) was prepared
containing the following reagents (5mL total volume): 4.7 mL ZY media, 5 µL of 1 M
MgSO4, 100 µL of 40% M glucose, 250 µL 20X NPS [Na2HPO4, KH2PO4, (NH4)2SO4]
mixed in 50 mL VWR tube. A BL-21 cell stock for Fbg αC (233-425) was added into the
prechilled ZYP.08G media and subjected to incubation at 27-28oC for 15 h at 180 rpm.
The cultured BL-21 cells were then transferred into filtered and sterilized ZYP5052 autoinducing media containing the following reagents: 1% tryptone, 0.8% glucose,
0.5% yeast extract, 0.2% lactose, 50 mM KH2PO4, 1 mM MgSO4, 50 mM Na2HPO4, 25
mM (NH4)2SO4, and 100 µg/mL ampicillin. The culture was incubated at 37oC at 225 rpm
for 2 h. The ZYP 50x5052 media provides a very suitable growth for activation of the
cultured E. coli BL 21 cells. Initially, the cells metabolize the limited amount of glucose
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as a preferred carbon source to generate a high-density culture without inducing the
expression of protein. After consuming glucose, the cells consume glycerol and lactose
where lactose promotes the activation of lac promoters and thus induce the expression of
RNA polymerase. This expression leads to transcription of the cloned DNA and translation
into protein. Optical density (OD) was monitored after the 2h period and when the OD
reached within 0.5 to 0.8, the heat was turned off, and the culture was subjected to
continuous incubation at 170 rpm for a 22h period at RT. A small volume (1 mL) of the
culture was also kept and stored in -20oC for SDS PAGE analysis.
Cultures were then collected and subjected to centrifugation at 8000 rpm in a JA10 rotor to obtain the biomass. The supernatant was then discarded, and E. coli wash buffer
was added to the pellets. The mixture was stirred in the cold room for about 40 min until
the pellets were fully homogenized. The bacterial suspension was then transferred evenly
into four 50 mL conical tubes and centrifuged at 5000 rpm (4oC for 30 min) using an
Allegra centrifuge with a SLC-4000 rotor. The supernatant was properly discarded. The
biomass pellets were stored at -20oC for SDS PAGE analysis.
Recombinant protein extraction and purification
The frozen biomass pellets were added to cold 50 mL E. coli lysis buffer (TBS)
containing 50 mM Tris acetate and 150 mM NaCl (pH 7.4). The resuspension was done by
vortexing the pellets vigorously and transferring them into a small beaker with a stirrer.
Protease inhibitors were then added: 40 mg Benzamidine chloride, Aprotinin (60 µL, 2 mg/
mL), pepstatin A (1 mM in isopropanol), and leupeptin (130µL, 40 mM). This step was
subsequently followed by the addition of 60 mg lysozyme and after 2 min, 30 mg SDC
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(Sodium deoxycholate) in 1 mL of the allotted buffer was added which made the lysate
viscous. In addition, 3 mL of 20% Triton X-100 and 200 µL of MgSO4 were added. DNase
(10 mg/mL) and RNase (10 mg/mL) were the last reagents added. Finally, the lysate was
transferred into the cold room for incubation and continuous stirring for 1.5-2h. The lysate
was then subjected to centrifugation using a Beckman JA-20 rotor at 13,500 rpm
(equilibrated at 4oC) for 20-25 min and filtered by vacuum filtration using a 0.45 µM filter.
The lysate was then filtered using a 0.2 µm membrane filter and the clarified lysate was
loaded onto a 1 mL capacity GST-trap affinity column attached to a Fast protein liquid
chromatography system (Akta Prime). Tris buffered saline (TBS) was used to wash the
column until the absorbance reached the baseline at 280 nm. The fibrinogen αC was
cleaved off from the GST-tag via in-column digestion using 100-200 µg HRV3C protease
incubated with the resin GST-Fbg αC at 4oC for 18 h. TBS was then employed to elute the
Fbg αC. To release the GST from the column, TBS with 20 mM reduced glutathione was
applied. Using a UV/VIS spectrophotometer, the absorbances of the eluted Fbg αC
fractions were measured at 280 nm and the concentration was determined using an
extinction coefficient of 12571 M-1 cm-1 for αC WT. Finally, the purity of the Fbg αC
fractions were checked by SDS PAGE (4% stacking gel and 15% resolving gel). The said
fractions were then stored at -80oC.
Monodansylcadaverine (MDC) incorporation assay
Nonproteolytic activation - Monovalent and divalent ions
A. FXIII A2 activation mixture using cations in the presence of 4 mM Ca
Nonproteolytic activation of FXIII A2 to FXIII-Ao was performed using an activation
mixture (20 µL) containing 2µM rFXIII A2, 50 mM Tris acetate buffer pH 7.4, a
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monovalent ion/divalent ion (LiCl, NaCl, KCl, CsCl, ChCl, TMAC, MgCl2, Li2SO4,
MgSO4) and 4 mM CaCl2. This 4 mM Ca2+ is expected to target the major Ca2+ binding
site (Cab1) on FXIII-A. For NaCl, KCl, and C5H14NO.Cl (Choline chloride or ChCl), the
monovalent cation concentrations tested were 150 mM, 350 mM, 425 mM, and 500 mM.
For TMAC (Tetramethylammonium chloride) and the rest of the ions (LiCl, KCl, CsCl,
Li2SO4, MgCl2 and MgSO4), a single 350 mM final concentrations of monovalent/divalent
cation was used in the activation reactions. The mixture was incubated for 1h at 37oC.

A. FXIII A2 activation mixture using 100 mM Ca
The concentration of calcium in Tris acetate buffer (pH 7.4) was raised to 100 mM and
no other monovalent or divalent ion was added. The mixture was incubated for 1 h at 37oC.
The 100 mM Ca2+ should be able to fill all Ca2+ binding sites (Cab1, 2 and 3) on FXIII.

2. Reaction mixture
A. FXIII reaction mixture using cations in the presence of 4 mM Ca
A volume of 8 µL of the activation mixture was added to the FXIII reaction mixture
giving a final volume of 160 µL and final concentrations of the reaction components: 100
nM FXIII, 4 mM Ca, 5 µM Fbg αC (233-425), 350 mM monovalent or divalent ions and 1
mM MDC all in Tris Acetate buffer. The reaction mixture had been equilibrated at 37oC
prior to the addition of the activation mixture.
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B. FXIII A2 Reaction mixture using 25 mM CaCl2
A transglutaminase assay that monitors the ability of the different activated forms
of FXIII-Ao to crosslink fluorescent MDC into the reactive Qs of Fbg αC (233-425) was
employed. The transglutaminase dependent reaction catalyzes isopeptide bond (γglutamyl-ε-lysyl) formation. To assess the extent of crosslinking at varying time points (2,
5, 7, 10, 15, 30, 45 min), 20 µL of the reaction mixture were added to a tube containing 7
µL of 5X reducing buffer (10% SDS, 0.5 M Tris pH 6.8, 40% glycerol, 0.02% bromophenol
blue, and 5% β-mercaptoethanol) for quenching. The time points were then further
quenched and prepared for SDS analysis by boiling each sample for 1 minute.
The quenched MDC crosslinking samples were run on SDS PAGE gels under
reducing condition (4% stacking gel and 15 % resolving gel). The sample volume was 20
µL per well. Prior to loading, the samples were vortexed and centrifuged shortly to get well
homogenized sample mixtures. Molecular weight marker (Precision plus, Biorad) and the
positive control, 5 µM of N, N-dimethylated β-Casein crosslinked to MDC with FXIII-A*,
was also loaded in the gel. Using a BioRad Geldoc system XRTM, UV light was used for
viewing the fluorescent bands. The gel was then stained with Coomassie blue-G250 so that
the protein amounts could be quantified and later normalized across different lanes. After
destaining the gel, an image was recorded of the protein bands under white light using the
same BioRad gel documentation system.
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β-Casein and monodansyl cadaverine crosslinking as positive control
Activation mixture
N,N dimethylated β-Casein, is a historical FXIII substrate derived from bovine
milk, and it was used to obtain a crosslinking positive control sample. In this study, βCasein serves as the glutamine donor instead of the fibrinogen. The positive control sample
(β-CaseinxMDC) was prepared by using proteolytically activated FXIII-A*. For the
proteolytic activation of FXIII A2 to FXIII-A*, the activation components with their final
concentrations were: 4 mM CaCl2, 58 nM recombinant human thrombin (rhIIa), and 2 µM
FXIII A2 all mixed in Tris acetate buffer (pH 7.4). This activation mixture was then
incubated at 37oC for 30 min. Phe-Pro-Arg Chloromethyl ketone (PPACK) uses a D-Phe
instead of a typical L-Phe. A 1 µL of PPACK (190 nm) was added to inhibit thrombin.

Reaction mixture
A volume of 24 µL FXIII-A* activation mixture was added to the reaction mixture
(4 mM CaCl2, 5 µM β-casein, and 1 mM MDC) making its total volume be 500 µL. This
mixture was then incubated for 6 min and subsequently added with 175 µL of 5x reducing
buffer for quenching and boiled for 5 minutes before being aliquoted in 600 µL microfuge
tube and stored at -80oC. For SDS PAGE runs, 20 µL of this positive control were loaded
into the gel (4% stacking gel and 15% resolving gel) and run under reducing conditions.
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Quantification and Statistics of MDC results
ImageJ 1.53e (NIH) was used to quantify the fluorescent and white light protein
bands generated from crosslinking of MDC-Fbg and the MDC-β-Casein. The exposure
time was taken at 64s under UV light. Three replicates were performed per each sample
tested. BioRad Molecular weight marker (Precision Plus ProteinTM) was used to monitor
the MW of the crosslinked MDC-Fbg and the β-Casein-MDC products. Each MDC-Fbg
band generated per time point was quantified against % fluorescent intensity of the control
(MDC-β-Casein) and normalized with the total protein signal from the Coomassie-stained
bands. Using the normalized fluorescence intensity data from three replicates, a graph was
plotted versus time (min).
Finally, using GraphPad Prism 9.0, a pseudo first-order kinetic fit was generated
using the equation model [Y=Yo + (Plateau – Yo) *(1- exp(-Kx)]. The Y represents the
fluorescence intensity (with FXIII), Yo the initial zero time point (no FXIIIAo), K the rate
constant, Y the value at infinite time, and x represents the time in minutes. Moreover, Oneway ANOVA using GraphPad Prism 9.2.0 was performed to determine whether there is
significant difference in the fluorescence intensities among different concentrations and
different ions tested. A probability value set at P<0.05 is automatically considered
significant.
Calculation of ionic strength
Ionic strength, abbreviated, µ, is defined as the total concentration of all ions in a
1

solution. Equation is given by µ = ∑𝑁𝑁 𝐶𝐶 × 𝑍𝑍 2 where Ci represents the molar
2

𝑖𝑖=1 𝑖𝑖

𝑖𝑖

concentration of cationic/anionic species and Zi, the charge of cationic/ anionic species
(95).
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RESULTS

In this study, nonproteolytic activation of FXIII A2 to FXIII-Ao was first achieved
by incubating the FXIII A2 with different monovalent ions (LiCl, NaCl, KCl, or CsCl) in
the presence of 4mM CaCl2 at 37oC for 60 min. FXIII-Ao transglutaminase activity was
then measured in terms of the normalized increase in gel-based fluorescence intensities
occurring as fluorescent monodansylcadaverine (Lysine mimic) was crosslinked to
fibrinogen αC (233-425) as a glutamine donor (Fig. 10).

Figure 10 Mechanism of isopeptide bond formation between reactive “Gln” of Fbg αC (233425) and “Lys” substrate MDC.

The salts tested in the present study were monovalent inorganic chloride-based salts
(LiCl, NaCl, KCl, and CsCl), monovalent and divalent sulfate-based salt (Li2SO4 a and
MgSO4), monovalent organic chloride-based salts (TMAC and ChCl), divalent chloridebased salts (CaCl2 and MgCl2). Different periodic properties of these ions are proposed to
influence FXIII activity. The table below shows the ionic radii (in pm) and ionic strengths
(µ, in M) of the cations tested.
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Table 2. Summary of periodic properties (Ionic radii and ionic strengths) of selected monovalent
and divalent salts.
Monovalent and Divalent ions
Periodic
properties

Li+

Na+

K+

Cs+

Mg2+

Ca2+

TMA+

Ch+

Cationic
radius (pm)

167

190

243

298

72

194

322

280

0.15b1

0.15c1

0.35

0.35

1.05f

0.35g

0.35h

Ionic
strength, µ,
(M)

0.35

a1

1.05a2

b2

c2

0.42

b3

0.50b4

1.05e1
0.35d
1.4e2

0.50c3

a1 = 350 mM LiCl, a2 = 350 mM Li2SO4, b1 = 150 mM NaCl, b2= 350 mM NaCl, b3 = 415 mM NaCl, b4 = 500 mM
NaCl, c1 = 150 mM KCl, c2= 350 mM KCl, c3 = 500 mM KCl, d = 350 mM CsCl, e1= 350 mM MgCl2, e2 = 350 mM
MgSO4, f = 100 mM CaCl2, g = 350 mM TMAC, h = 350 mM ChCl.

MDC incorporation assay: FXIII activation using NaCl with 4 mM Ca
The NaCl concentrations used ranged from a physiological concentration of 150 mM
NaCl to the supraphysiological concentrations of 350 mM, 425 mM, and 500 mM NaCl,
all in the presence of 4 mM CaCl2. The fluorescent bands, products of MDCxFbg αC
crosslinking, were recorded under UV light. The Coomassie blue stained gels, recorded
under white light, contain bands representing the amount of protein loaded in each of the
lanes of the gel. As shown in Fig. 11A, as the NaCl concentrations increased, the
fluorescent crosslinking bands also increased in intensity over time.
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Figure 11. MDC assay results of FXIII A2 with NaCl. A) Gel images of fluorescent
MDCxFbgαC (top) and Coomassie blue stained gel (bottom) B) Plot of normalized in-gel
fluorescence intensity C) Bar graph of normalized in-gel fluorescence intensity at 30 min

As graphically shown in Fig 11B, NaCl helps promote an increase in MDC
incorporation into Fbg αC (233-425) over time in the presence of 4 mM CaCl2. At the 30
min time point, there is a significant difference in the crosslinked FLR intensity for all the
NaCl concentrations relative to 500 mM NaCl. The 500 mM NaCl reactivity is 1.5-fold
higher at 30 min than 425 mM NaCl, 5-fold higher than 350 mM NaCl, and 10-fold higher
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than 150 mM NaCl. In summary, the MDC incorporation into Fbg αC increases with
increasing NaCl concentration which may provide a suitable additional electrostatic
surface environment during nonproteolytic FXIII activation.

FXIIIAo using NaCl vs Ca
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500 mM NaCl

150 mM NaCl

425 mM NaCl

Figure 12. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao with NaCl vs FXIII-Ao

with CaCl2

Fig. 12 shows how FXIII activated at the higher 100 mM CaCl2 reaches a plateau
for MDC incorporation at a much faster rate (K) than the NaCl series (all with 4 mM
CaCl2). A large increase in MDC incorporation rate into Fbg αC (233-425) is observed
using 100 mM Ca2+ versus a combination of NaCl (150-500 mM) and 4 mM CaCl2. The
500 mM NaCl condition achieved a similar final fluorescence response as that of 100 mM
CaCl2 but required longer time points. Furthermore, the rate constant (K) of NaCl increased
from 150 mM to 425 mM but slowed down slightly at 500 mM. Faster plateau formation
was observed at 425 mM NaCl. At 150 mM, the K is very low and plateau formation is
also not observed by 45 min (See Table. S1 in the supplemental table).
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MDC incorporation assay: FXIII activation using KCl
Three concentrations of KCl were tested (150 mM, 350 mM and 500 mM) with 4 mM
Ca to evaluate the effect of these varying concentrations of monovalent ion on FXIII’s
transglutaminase activity. Fig. 13a shows the SDS PAGE gel images of the MDC assay
and then Fig. 13b the plot of fluorescence intensity with increasing KCl concentrations as
a function of time.
Similar to the fluorescence intensity trend of 150 mM to 500 mM NaCl, Fig. 13a shows
that increasing KCl concentrations increases transglutaminase activity for FXIII-catalyzed
crosslinking of MDC into Fbg αC (233-425). Furthermore, the plateau formation with 500
mM KCl clearly displays a much faster (K) rate to reach a crosslinking plateau than the
350 mM (0.015 min-1 vs 0.08 min-1) whereas the 150 mM KCl does not show plateau
formation at all. This effect is similar to the fluorescence intensity response exhibited by
150 mM NaCl. Increasing the KCl concentration from 350 to 500 increased the FLR
intensity by about ~1.5-fold and ~3.0-fold when elevated from 150 mM to 500 mM KCl.
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Figure 13. A. MDC assay results of FXIII A2 with KCl. A) Gel images of fluorescent
MDCxFbgαC (top) and Coomassie blue stained gel (bottom) using FXIII-Ao,KCl B) Plot of
normalized in-gel fluorescence intensity C) Bar graph of normalized in-gel fluorescence intensity
at 30 min reaction time.

Comparing FXIII activation using KCl and NaCl
Both NaCl and KCl are physiologically present intra and extracellularly. Although
NaCl effects have been well studied in coagulation systems (96,97), KCl is another
potential ion of interest to study as it is also the most abundant cation intracellularly.
Starting with the lowest concentration, 150 mM KCl and 150 mM NaCl show no plateau
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formation even at longer reaction periods, but the final transglutaminase activity is higher
for KCl than NaCl. For the 350 mM concentrations, KCl still promoted higher FXIII
crosslinking activity than NaCl. At 500 mM concentration, KCl and NaCl both increased
the formation of the MDC-Fbg product by the same amount at the 30 min reaction period,
but KCl reached the fluorescence plateau earlier than 500 mM NaCl and obtained a much
higher rate constant (K) at 500 mM and 350 mM concentrations. In this case, NaClpromoted transglutaminase activity takes longer time to saturate, and consequently, will
have a higher plateau value.
FXIIIAo NaCl vs KCl with 4 mM Ca
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Figure 14. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao with KCl vs FXIII-Ao
with NaCl

FXIII activation using 350 mM monovalent cations (LiCl, NaCl, KCl, and CsCl)
Results from the transglutaminase studies done in the presence of Na+ and K+ led
to interest into examining two other Group 1 cations, Li+ and Cs+. For this monovalent
cation series, the ionic radii included: Li+ (180 pm), Na+ (227 pm), K+ (280 pm), Cs+ (343
pm). Among these Group 1 cations, only NaCl has been extensively studied in the past for
FXIII transglutaminase activity (48,63). With these four-cation series, trends in MDC
incorporation into Fbg αC were examined relative to cationic sizes (180 – 343 pm). In the
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MDC assays, all the monovalent cations had the same concentration (350 mM). Figure 15
displays all the fluorescent bands generated in the crosslinking of MDC and Fbg αC WT
in SDS PAGE gels. To correlate these gel results, a plot was created to show the different
responses of these ions in terms of their normalized fluorescence intensities that reflect
increases to FXIII-Ao activity.
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Figure 15. A. MDC assay results of FXIII A2 with monovalent ions. A) Gel images of fluorescent
MDCxFbgαC (top) and Coomassie blue stained gel (bottom) using FXIII-Ao,LiCl , FXIII-Ao,NaCl ,
FXIII-Ao,KCl and FXIII-Ao,CsCl B) Plot of normalized in-gel fluorescence intensity C) Bar graph of
normalized in-gel fluorescence intensity at 30 min reaction time.

Comparing the transglutaminase activities of these monovalent ions after 30 min
reaction period, the FLR intensity of CsCl surpassed KCl by about ~1.4-fold (0.052±0.002
vs 0.038±0.003). There is an even higher difference between CsCl vs NaCl, with an
increase in fluorescence intensity of about ~2.0 fold (0.052±0.0025 vs 0.024±0.0001) with
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P≤0.0001. The highest significant difference that was observed in terms of FXIII activity
was between CsCl and LiCl by ~4.0 fold (0.052±0.0025 vs 0.038± 0.0015) at P≤0.001.
Meanwhile, there was a ~2-fold increase in fluorescence intensity going down the group
from Li+ to Na+. In summary, increasing ionic radii of the Group 1 cations, led to increases
in the FXIII-Ao transglutaminase activity for crosslinking MDC into Fbg αC (233-425).
For the rate constants generated by these ions, CsCl obtained the highest crosslinking rate
value (0.029 min-1) followed by LiCl (0.025 min-1), KCl (0.015 min-1), and NaCl (0.010
min-1) (See Table. S1 in the supplemental table).

FXIII activation using 350 mM monovalent cations LiCl2 vs Li2SO4
The effect of monovalent cationic salts containing Cl- anions were already
evaluated through the MDC incorporation assay. In this study, the effect of divalent SO4-2
was assessed using Li2SO4. In physiological intracellular and extracellular environments,
SO4-2 is also present, making this divalent anion also valuable to evaluate the effect on
FXIII-A transglutaminase activity. Based on the MDC-Fbg crosslinking by FXIII-Ao LiCl
exhibited the lowest transglutaminase activity of the Cl- containing monovalent ions.
Surprisingly, Li2SO4, exceeded the crosslinking ability of FXIII-Ao + LiCl by about ~3.6
fold (0.057 min-1 vs 0.016 min-1) after 30 min reaction time with p≤0.001 (See Fig. 16).
Overall, Li2SO4 which has a higher ionic strength (µ = 1.05) than LiCl (µ = 0.35) exhibited
a much higher transglutaminase activity than LiCl and even Na+ and K+. Interestingly,
Li2SO4 promoted similar fluorescence transglutaminase activity as CsCl, which has the
largest ionic size among the four monovalent ions tested. In summary, Li2SO4 promoted
nonproteolytic FXIII activation at a level comparable to CsCl.
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Figure 16. A. MDC assay results of FXIII A2 with NaCl, LiCl, and Li2SO4. Gel images of
fluorescent MDCxFbgαC (top) and Coomassie blue stained gel (bottom) using FXIII-Ao,LiCl,
FXIII-Ao,Li2SO4 and FXIII-Ao,CsCl B) Plot of normalized in-gel fluorescence intensity C) Bar graph
of normalized in-gel fluorescence intensity at 30 min reaction time.

FXIII activation using organic monovalent salts ChCl and TMAC
Organic salts choline chloride (ChCl) and tetramethylammonium chloride (TMAC)
were also compared in terms of their effects on transglutaminase activity of FXIII. Both
compounds contain a positively charge nitrogen center covalently bonded with four
carbons. The only difference in the structure of these two quaternary salts is that the
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nitrogen center in TMAC contains 4 methyl groups but ChCl contains 3 methyl groups and
one hydroxyl group.

Tetramethylammonium chloride

Choline chloride

Figure 17. Structures of organic salts Tetramethylammonium chloride (TMAC) and Choline
Chloride (ChCl)

FXIII-Ao using 350 mM ChCl revealed a much lower rate of MDC incorporation
into the Fbg αC fragment as compared to 350 mM NaCl by about ~3.0 fold after a 30 min
reaction period (See Fig. 18b). These organic salt compounds can help probe whether FXIII
contains a distinct Na+ binding site. Unlike the blood coagulation thrombin that has a strict
requirement for Na+ binding (98), FXIII can still use the cationic and ionic strength
properties of TMAC and ChCl to perform some crosslinking activity although at a slower
rate than NaCl. The larger ionic size of Ch+ (329 pm) is not as well accommodated as the
smaller TMA+ (280 pm).
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Figure 18. A. MDC assay results of FXIII A2 with TMAC and ChCl. A) Gel images of fluorescent
MDCxFbgαC (top) and Coomassie blue stained gel (bottom) using FXIII-Ao,NaCl , FXIII-Ao,TMAC
and FXIII-Ao,ChCl B) Plot of normalized in-gel fluorescence intensity C) Bar graph of normalized
in-gel fluorescence intensity at 30 min reaction time.

When comparing the result of ChCl with other monovalent ions tested, it appears
that ChCl overlaps with LiCl which suggests that they have similar abilities to support
FXIII activity (Fig. 19).
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FXIIIAo using TMAC, ChCl and LiCl with 4 mM Ca2+
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Figure 19. Plot of Normalized in-gel fluorescence intensity using FXIII-Ao,TMAC, FXIII-Ao,ChCl and
FXIII-Ao,LiCl

FXIII A activation using Divalent ions 350 mM MgCl2 and MgSO4
Studies with Group 1 monovalent ions demonstrated that these ions could
increase FXIII activity in a manner directly proportional to the ionic sizes of these ions.
Moreover, the fluorescence intensities with Li2SO4 exceeded that of LiCl making SO4-2
also a good target to evaluate its effect on FXIII activation. Li+ is the smallest ion (167 pm)
in the Group 1 whereas in Group 2, physiological Mg2+ also has smaller ionic radius (72
pm). Since there was difference in the transglutaminase activity of FXIII when LiCl and
LiSO4 were tested, now MgSO4 was also compared with MgCl2.
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Figure 20. A. MDC assay results of FXIII A2 with CaCl2, MgCl2, and MgSO4. A) Gel images of
fluorescent MDCxFbgαC (top) and Coomassie blue stained gel (bottom) using FXIII-Ao, CaCl2,
FXIIIAo, MgCl2 and FXIII-Ao,MgSO4 B) Plot of normalized in-gel fluorescence intensity C) Bar graph
of normalized in-gel fluorescence intensity at 30 min reaction time.

MgSO4 turned out to be a more-preferred divalent salt than MgCl2 for
nonproteolytic FXIII activity in the presence of 4 mM CaCl2. The MgSO4 increased the
MDC incorporation amount by about 3-fold at the 30 min reaction time point relative to
MgCl2 (0.078±.00078 vs 0.026±0.0032) at P≤0.0001. Furthermore, MgSO4 also exhibited
the highest fluorescence intensity among all the ions tested (except 100 mM CaCl2) for
41

MDC incorporation assays (See Fig. 20b). The MgCl2 generated a higher rate constant (K)
than MgSO4 (0.048 vs 0.057). In addition, there was no significant difference in the
fluorescence intensity at the 30 min reaction time between CaCl2 and MgSO4. Also,
saturation forms faster for MgCl2 (0.0261 to 0.040) than MgSO4 (0.097 to 0.105).
Moreover, in terms of rate constant (K), Ca2+ generated the highest value which is ~4.5
fold higher than MgCl2 and MgSO4 (See Table. S1 in the supplemental table). The ionic
strength of MgSO4 is 1.4 which is much higher than that of MgCl2 which is only 1.05. The
sulfate containing salts of Li+ and Mg2+ revealed a relatively much higher transglutaminase
activity than LiCl and MgCl2.
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Discussion
It is well established that cellular FXIII undergoes nonproteolytic activation
transitioning from a zymogen dimer (FXIII A2) to active monomer (FXIII-Ao) at high mM
calcium concentration. Before activation, the cytoplasmic calcium level is only 0.0001
mM (79). This calcium level can become elevated to a supraphysiological concentration
following release of Ca2+ by the endoplasmic reticulum (99) in bone marrow cells. The
cytosolic environment not only contains Ca2+, in fact, K+ (150 mM) is the dominant ion
followed by Mg2+ (17-20 mM). Several other ions (Cl-, Na+, SO42-, etc.) also exist (see
Table 1). In addition, some cations may be present in the human body due to medications
such as Li+ (100) for psychiatric medicine or Cs+ for cancer treatment (101).
The research project described herein first examined the Group 1 cations Li+, Na+,
K+, and Cs+. In most assays monitoring for FXIII transglutaminase activity, the TrisAcetate buffer environment includes 150 mM NaCl which is the physiological
concentration in plasma in the presence of Ca2+. NaCl effects have previously been
demonstrated to help increase FXIII activation/activity (48,63). Interestingly, K+ levels are
higher than Na+ in the intracellular platelet environment due to the Na+K+ ATPase pump
that maintains low Na+ concentration inside the cell (102). The FXIII B2 subunits in plasma
help prevent premature activation of catalytic FXIII A2 in the presence of Na+ and K+ (48).
Polgar et al. suggested that NaCl or KCl could be used as an ancillary ion to support
enzymatic activity (48), but no assay data were presented for KCl. The paper also did not
state which of these cations promoted higher transglutaminase activity. The FXIII
catalyzed MDC-incorporation assays used in the present study employed 150 – 500 mM
cationic salts in the presence of 4 mM CaCl2. Based on an estimated KD of 100µM, the 4
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mM Ca2+ should occupy the main FXIII calcium binding site Cab1(63). For the NaCl and
KCl studies, the higher the salt concentration the more FXIII transglutaminase activity was
observed which also suggests more conversion to active monomeric forms (FXIIIAo) has
been achieved (60).
One of the major differences between Na+ and K+ is their ionic size. K+ with a larger
ionic radius (243 pm) supported higher transglutaminase activity than Na+ (190 pm).
Cationic ionic radius may affect the electrostatic protein surface of FXIII. Moreover, both
Na+ and K+ showed increased MDC incorporation when ionic strengths (µ) of both ions
increased from 0.15 M to .42 M. This increase in cationic concentration combined with
constant low mM Ca2+ concentration suggested that Na+ and K+ supported Ca2+ in FXIII
and substrates interactions. For two other monovalent Cl--based salts (LiCl and CsCl), 350
mM LiCl (167 pm) exhibited the lowest MDC incorporation rate whereas the larger ionic
350 mM CsCl (298 pm) promoted the highest incorporation rate exceeding all the other
monovalent ions tested. Overall, the order of promoting reactivity matched the changes in
ionic radius with Cs+ > K+ > Na+ > Li+.
The cationic salts examined were all Cl- based. The focus could therefore be on the
cations since the anion Cl- has very low or no interaction with protein surfaces (103). The
organic salts ChCl and TMAC were also probed. These salts could support FXIII
transglutaminase activity, but the rates of MDC incorporation into Fbg αC (233-425) were
much slower than Na+.
Current studies also explored the effects of the anion in the salt pairing. Li2SO4
generated a much higher transglutaminase activity by 3.6-fold than LiCl. Moreover, LiCl
and Li2SO4 have different ionic strengths (at 350 mM), µ= 0.35 M and µ= 1.05 M,
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respectively. The documented enhancements in crosslinking ability observed with Li2SO4
suggest an additional importance of ionic strength (µ) in promoting FXIII activity. Another
study on the effect of anions focused on MgCl2 vs MgSO4. Magnesium ranks second in
terms of cation concentration inside the cell and is fourth in the whole body (78). The
results herein showed that MgSO4 (µ=1.40 at 350 mM) generated a 3-fold higher FXIII
transglutaminase activity than MgCl2 (µ = 1.05 at 350 mM). Hence as observed with
lithium-based salts, increasing ionic strength supported an increase in FXIII
transglutaminase capability.
Importantly, 100 mM CaCl2 promoted the greatest transglutaminase activity and
achieved the fastest approach to a Fbg αC – MDC crosslinking reaction plateau. These
effects can be correlated with more extensive calcium binding to FXIII at up to three
different sites within the catalytic core domain (Cab1, Cab2, and Cab3). Previously
published Molecular Dynamics simulations involving FXIII A2 in 1 M NaCl reported that
Na+ alters the overall surface electrostatic distribution on FXIII (63). Such results suggest
that FXIII does not have a distinct Na+ binding site with a major impact on FXIII structure.
The authors proposed instead that Na+ creates disturbances in the pKa values of internal

Figure 21. Metal binding to amide of protein backbone mimic (Butyramide). Calcium (Yellow),
Sodium (Blue). Figure is adapted from Cremer Research group (J. Am. Chem. Soc. 2013, 135,
13, 5062–5067)
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buried residues with a possible impact on domain-based interactions (63). Interestingly, the
Cremer lab examined several Group 1(Alkali) and Group 2 (Alkaline) ions and found that
only Ca2+ makes a strong interaction with the carbonyl of butyramide (Fig. 21) whereas
other cations only bind very weakly (104). Similar effects are expected for the sequence
of amino acids that make up FXIII A2.
Another interesting insight to explain the role of Ca2+ or Na+ in FXIII comes from
reviewing the results of amide proton to deuterium exchange studies coupled with mass
spectrometry (HDX-MS). Woofter et al monitored for changes in FXIII amide proton
solvent accessibility in the presence of Ca2+ and Na+ ions (105). Results in this study
revealed that similar to the effect of Ca2+, high mM Na+ helps promote exposure of FXIII
amino stretches 220-230 (Q-substrate binding region), 240-270 (dimer interface), and 300314 (FXIII active site) (105). The monovalent ion (Na+) may thus be a valuable player in
further supporting local and long-range conformational changes to FXIII that are otherwise
dominated by Ca2+ binding.
Overall, for the monovalent ions, FXIII-A transglutaminase activity was found to
be directly proportional to the increasing ionic radius of Group 1 cations containing Cl-based salts. In addition, increasing ionic strength in the presence of sulfate anions tended
to exhibit additional benefit for FXIII activation and subsequent transglutaminase
crosslinking ability. This study also highlighted the first report of the effect of LiCl, CsCl,
MgSO4, and Li2SO4 in FXIII activation. The order effect of the ions towards FXIII A2
activation in the present study was CaCl2 > MgSO4 > Li2SO4 ≈ CsCl > KCl > MgCl2 > NaCl
> TMAC > LiCl > ChCl. This study provides valuable information on how specific cations
and anionic species influence FXIII activation and function. Furthermore, the data could
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help researchers optimize ionic conditions for examining proteolytic or nonproteolytic
activation or activity of FXIII.
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CHAPTER III
MONITORING INTRINSIC FLUORESCENCE OF HUMAN FXIII ACTIVATED
FORMS UNDER DIFFERENT MONOVALENT AND DIVALENT SALTS
Introduction
Conformational monitoring studies of FXIII A2 are of critical importance since this
enzyme’s activation is greatly dependent on a series of large protein domain
rearrangements. Since FXIII A2 contains aromatic amino acids, intrinsic fluorescence can
be measured following excitation at 280 nm (106). Tryptophan (W or Trp) gives the highest
quantum yield which is defined as the ratio of photons emitted, and photons absorbed
(95,107). Among the three intrinsic fluorophores: Phenylalanine (F), Tyrosine (Y), and
Tryptophan (W). FXIIIA contains 15 tryptophan residues (W57, W130, W164, W187,
W225, W279, W292, W315, W370, W375, W379, W392, W664, W691, and W698- PDB
ID: IF13) concentrated within the Cab2 and Cab3 regions located in the FXIII catalytic
core domain (Fig. 22) (52,108).
Sixty percent of the FXIII Trp residues (W187, W225, W279, W292, W315, W370,
W375, W379, W292) are located within the catalytic core region that is covered by β barrel
1 and 2. β barrel 1 itself contains 3 Trp residues (W664, W691, and W698) whereas no
Trp residues are in β barrel 2. The β sandwich domain contains 3 Trp residues (W57, W130,
and W164). Upon FXIII A2 activation to FXIII-Ao, the catalytic core region where most of
the tryptophan residues

(9 Trp) are located becomes more exposed. Tryptophan
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flourescence is sensitive to changes in the local environment such as the presence of ions.
Fluorophores encountering less polar environment tend to increase λmax and moves to
shorter wavelengths whereas with high polar environment λmax decreases. Neighboring
protonated acidic groups quench Trp residues (109).

A

B

Figure 22. FXIII active and inactive structure containing tryptophan residues. FXIII showing all
the 15 Tryptophan residues (sky blue) distributed on the catalytic core (9 Trp), β Barrel I (3 Trp),
and β sandwich domain (3 Trp). A) FXIII A zymogen in inactive state (PDB IF13). B) FXIIIAo
bound with calcium + inhibitor in the trapped open conformation (PDB 4KTY).

In the crystal structure of FXIII (Fig. 22), the two β barrel domains which cover the
catalytic core (where 60% of all the Trp residues are located) are largely moved away upon
calcium binding as FXIII goes from an inactive to active state. The changes in the emission
spectra of FXIII A2 are an indication of a change in conformation.
In the case of FXIII A2, fluorescent changes are proposed to monitor the movement
of the β barrel domains to expose the Trp residues in the catalytic core. At high enough
Ca2+ concentration, dissociation into monomers may also be occurring. Prior studies using
AUC (analytical ultracentrifugation) and size exclusion chromatography methods have
documented a shift from FXIII A2 dimer into monomer at high calcium conditions (60).
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In this study, selected monovalent and divalent salts were tested for their abilities
to induce changes in the intrinsic fluorescence of FXIII A2 which could help explain the
transglutaminase results obtained from the MDC assay.
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Materials and Method
Intrinsic tryptophan fluorescence study
The primary goal for the fluorescence studies was to obtain more information on
the conformational changes FXIII undergoes upon activation. Previous published studies
reported on FXIII fluorescence properties at room temperature in the presence of 100 mM
MgCl2 or 100 mM CaCl2, both in borate buffer solution (61). The current study focused
on the inorganic monovalent ions (LiCl, Li2SO4, NaCl, KCl, CsCl) and a set of divalent
cations (MgCl2 and MgSO4). In addition, this study also monitored the effects of room
temperature versus physiological temperature on the emission spectra.
Effect of monovalent and divalent cations with low calcium level
A Perkin Elmer LS 55 fluorimeter was used to evaluate the influence of different
monovalent/divalent cations and incubation temperatures on the fluorescent intensity of
FXIII A2. Using the FLwinLab software, the sample was excited at 280 nm and scanned
from 290 to 400 nm at a speed of 100 nm/min. For these experiments, the excitation and
emission slits were adjusted to 3.5 nm.
The fluorescence emission spectrum of 500 nM FXIII A2 in 20 mM Borate (pH 7.8)
buffer served as a control sample. These FXIII concentrations and buffer environments
were chosen so that conformational effects could be compared with earlier studies by
Anokhin et al. 2017 (61). For the current research, a 500 µL total solution volume was
prepared containing 500 nM FXIII A2, 20 mM borate buffer (pH 7.8), and a monovalent
and/or divalent cation (350 mM). Fluorescence measurements were then made in a 500
µL quartz cuvette. Emission spectra were collected at room temperatures after 10-, 20- and
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30-minutes of incubation. Subsequently, a small volume of calcium stock solution was
added to achieve a final concentration of 4 mM Ca2+. This cation concentration would fill
up Cab1, the main calcium binding site of FXIII. Fluorescence responses (at room
temperature) were monitored again after 10-, 20-, and 30-mins. Immediately after these
measurements, the mixture was incubated for 30 min at 37oC, and the spectra were
measured again following the same time intervals described above.
Effect of Calcium with and without 150 mM NaCl
FXIII emission spectra were collected at different calcium concentrations with and
without NaCl in Borate buffer. The NaCl concentration was kept at a plasma physiological
concentration of 150 mM (80,110). To perform this experiment, FXIII’s fluorescence
responses were examined for the following conditions: (1) 20 mM Borate buffer, 500 nM
FXIII A2 and 4 mM CaCl2, (2) 20 mM Borate buffer, 500 nM FXIII A2, and 150 mM NaCl,
(3) 20 mM Borate buffer, 500 nM FXIII A2, 4 mM CaCl2, and 150 mM NaCl, (4) 20 mM
Borate buffer, 500 nM FXIII A2, 100 mM CaCl2, (5) 20 mM Borate buffer, 500 nM FXIII
A2, 100 mM CaCl2, and 150 mM NaCl. Furthermore, all these conditions were done at
room temperature and at physiological temperature (37oC).

Control experiment using free Tryptophan
A solution of free tryptophan was prepared by dissolving 100 mg of Tryptophan in 15 mL
dI H2O (633 mM Trp). Using 2 mL quartz cuvette, a mixture with a final concentration of
0.65 mM Trp and 350 mM salts (CaCl2 and monovalent salts) was excited at 280 nm and
scanned from 290 to 450 nm at a speed of 100 nm/min at room temperature. The effect of
CaCl2 and CsCl (8 mM, 16 mM, and 64 mM) to free Trp was also compared.
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Results
FXIII A2 in 20 mM Borate solution
The emission spectra results for FXIII A2 in borate revealed no change in the
maximum FLR intensity when the temperature was elevated from room temperature to
37oC. The maximum intensity at room temperature was 26.9 whereas that at 37oC was 26.5.
Any subsequent changes observed would report on conformational properties influenced
by particular cations, local environment polarity, and new influences from temperature.
FXIII at RT and 37oC
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Figure 23. Emission spectra of FXIII A2 in borate buffer at room temperature and 37oC

FXIII A2 with 150 mM NaCl vs 4 mM CaCl2 and 100 mM CaCl2
Plasma Na+ concentration is around 142-150 mM (72) whereas the Ca2+
concentration typically used for in vitro studies is 2.5 mM Ca2+ . In this experiment, the
effects of 4 mM Ca2+ vs 150 mM NaCl were probed. At 25oC, the FLR intensity of FXIII
in 150 mM NaCl exhibited a similar 24 % decrease in FLR as FXIII in 4 mM CaCl2. When
the temperature was elevated to 37oC for 30 min, the maximal fluorescent intensity of
FXIII+ 4 mM CaCl2 decreased by 44% which is almost 2-fold greater than the effect of
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150 mM NaCl which only exhibited a FLR decrease of 25.4% when the temperature was
raised to 37oC. Moreover, increasing the calcium concentration up to 100 mM CaCl2
resulted in an even greater decrease in maximum intensity of 66% (See Table. S2 in the
supplemental table).
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Figure 24. Emission spectra comparison of NaCl vs CaCl2. A) FXIII +150 mM NaCl B) FXIII
+ 4 mM CaCl2 C) FXIII +100 mM CaCl2 all at RT and 37oC. D) Maximum intensity comparison
of FXIII +150 mM NaCl vs FXIII + 4 mM CaCl2 all at RT and 37oC. The asterisk represents the
p values (* =P≤0.05, **=P≤0.01, *** P≤0.001, **** = P≤0.0001, ns, not significant = P≥0.05).
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In previous studies by Anokhin et al 2020, 100 mM Ca alone induced full
nonproteolytic activation of FXIII A2 to FXIII-Ao as compared to 4 mM CaCl2 which
showed slow FXIII activation (60). As with the FLR result mentioned above, there was a
larger decrease in FLR intensity for 100 mM CaCl2 than the 4 mM CaCl2.
Emission spectra of FXIII A2 with Monovalent ions (LiCl, NaCl, KCl, and CsCl)
Calcium effects on FXIII A2 conformational change have already been well studied
(36,52), but reports on the effect of sodium are limited. By contrast, other cations such as
LiCl, KCl, and CsCl have not yet been explored. Among the monovalent ions in Group 1
of the periodic table, MDC crosslinking studies demonstrated (chapter 2) that NaCl can act
as an auxiliary ion for FXIII A2 activation by 4 mM Ca2+. From top to bottom of the Group
1 elements, Li+ has the smallest atomic radius followed by Na+, K+ and Cs+. A drop in
maximal FLR intensity occurred when these monovalent cations were combined with 4
mM Ca at room temperature (LiCl-19%, NaCl-29%, KCl-30%, and CsCl-49%). When ion
combinations (350 mM monovalent salt + 4 mM Ca) were incubated at 37oC, the decrease
in maximal FLR became even larger: LiCl-34%, NaCl-43%, KCl-45%, and CsCl-49%.
Furthermore, the Na+ and the K+ generated very close values at RT and 37oC. In summary,
the 4 mM Ca2+ acts as the main driving force for conformational change and these effects
increase with temperature. The monovalent ions tend to introduce additional, smaller
supporting effects. Similar to MDC crosslinking assay, the decrease in maximum intensity
increased in percentage as ionic size of the monovalent ions increased.
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Figure 25. Emission spectra of FXIII A2 with monovalent ions under RT and 37oC A) Emission spectra of
FXIIIA2 + 350 mM LiCl, B) FXIIIA2 + 350 mM NaCl, C) FXIIIA2 + 350 mM KCl, D) FXIIIA2 + 350 mM
CsCl under RT and 37oC. E) Maximum intensity of FXIIIA2 + 350 mM LiCl, 350 mM NaCl, 350 mM KCl,
350 mM CsCl all with 4 mM CaCl2 under RT and F) 37oC. The asterisk represents the p values (* = p≤0.05,
**=p≤0.01, *** p≤0.001, **** = p≤0.0001, ns, not significant = p≥0.05).
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When working with Trp residues, there may be concerns that the Trp fluorescence
is being quenched by Cs+ (Komiyama et al 1979). Therefore, control experiments (Supp.
Fig. S2) were performed comparing the effects of 350 mM CaCl2 and 350 mM
monovalent ions (LiCl, NaCl, KCl, and CsCl) on free Trp. Of these cations, only CsCl
showed a substantial decrease in maximal intensity which confirms that CsCl can be a
Trp quencher. At varying concentrations of CsCl or CaCl2 (8 mM, 16 mM, and 64 mM),
no changes in maximal Trp fluorescence intensities were observed with CaCl2 whereas a
gradual increase in CsCl concentration led to a gradual increase in Trp quenching. By
contrast, the effects of CsCl on intact FXIII were far more modest than those with CaCl2.
FXIII contains three Ca2+ binding sites that upon Ca2+ binding cause FXIII to expose its
catalytic core where 60% of the 15 Trp residues are located.
350 mM Li2SO4 vs 350 mM LiCl
LiCl contributed the smallest decrease in the fluorescence effect among the Clcontaining monovalent ions (Cl- containing anions). This experiment aimed to determine
the effect of the counter ion Cl- vs SO4-2. At room temperature, 350 mM LiCl and 350 mM
Li2SO4 combined with 4 mM CaCl2 exhibited 19 and 24% drops in intensity, respectively.
Finally, when these samples (350 mM LiCl or Li2SO4 with 4 mM CaCl2) were incubated,
the maximum intensity drop, 32-34%, did not show significant difference. These results
suggest that the counter ions (Cl- or SO4-2) of Li+ play minimal roles, and cation Ca2+ is still
the main contributor to FXIII conformational change. The effects of anions were more
dominant in crosslinking studies involving the MDC assay most probably due to much
higher ionic strength of Li2SO4 over LiCl (Chapter 2).
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Figure 26 A) Emission spectra of LiCl vs Li2SO4 at RT and 37oC. Emission spectra of
FXIII-A2 + 350 mM LiCl B) FXIII-A2 + 350 mM Li2SO4 under RT and 37oC. C and D)
Maximum intensity of FXIII + 350 mM LiCl and FXIII-A2 + 350 mM Li2SO4 under RT
and 37oC. The asterisk represents the p values (* = p≤0.05, **=p≤0.01, *** p≤0.001, ****
= p≤0.0001, ns, not significant = p≥0.05).
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FXIII A2 with 350 mM MgCl2 vs 350 mM MgSO4
MgCl2 has also been previously studied as an auxiliary ion in FXIII activation. The
concentration of this divalent cation magnesium intracellularly is between 17-20 mM
(73,77,78) whereas extracellularly is only about 0.7-1.08 mM (111) making the
intracellular Mg2+ level 20-fold higher than in plasma. There is only a very small difference
on the emission spectra generated by MgCl2 and Mg2SO4 when 4 mM CaCl2 (at room temp)
was combined with them, the drop in intensities recorded were 28% and 29%, respectively.
Even when these samples were incubated at 37oC for 30 min, only a slight difference in
intensity were generated: 38% for MgCl2 and 39% drop for Mg2SO4 (See Table. S2 in the
supplemental table). Counter ions of Mg2+ (Cl- or SO 42-) showed a similar trend like the
LiCl vs Li2SO4 with only the cations playing a role in promoting conformational change.
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Figure 27. Emission spectra of (A) FXIII + 350 mM MgCl2 and (B) FXIII + 350 mM
MgSO4 under RT and 37oC. Maximum intensity of (C) FXIII + 350 mM MgCl2 vs (D)
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Discussion
Tryptophan is the dominant amino acid for protein fluorescence (112). When
tryptophan residues within a protein experience an increase in the polarity of their
surrounding environments, a decrease in the intensity of the emission spectrum is observed.
Such changes can be correlated with alterations in the conformational properties of the
protein (95). Previous studies demonstrated that FXIII A2 in the presence of 100 mM CaCl2
undergoes a significant decrease in fluorescent emission intensity. The same effect cannot
be mimicked by the divalent cation Mg2+ (60). Both HDX-mass spectrometry (105) and
X-ray crystallography (52) have previously documented that FXIII A2 undergoes
conformational changes in the presence of increasing concentrations of Ca2+. Moreover,
Ca2+ ions can interact with FXIII A2 at up to three binding regions (Cab1, 2 and 3) (52).
The MDC crosslinking studies described in Chapter 2 that involved 4 mM Ca2+
revealed that as the atomic radii of supporting monovalent cations increased, the FXIII
transglutaminase activity also increased with a ranking of (Cs+ > K+ > Na+ > Li+). The
current project described in Chapter 3 focused on using fluorescence emissions spectra to
monitor FXIII A2 for conformational changes occuring in the presence of these different
monovalent cations.
On their own, the monovalent cations showed a modest ability to quench maximal
FLR intensity. More of the fluorescence decrease occurred in the presence of 4 mM CaCl2,
a concentration that would target the major FXIII calcium binding segment Cab1. In the
presence of such low mM Ca2+, 350 mM NaCl or KCl had greater benefits than 150 mM .
The monovalent cations and their contributions to increasing ionic strength are proposed
to support changes in the FXIII conformation beyond that provided by Ca2+. The decreases
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in fluorescence intensity occurred with a ranking of monovalent cations that matched the
ionic radii (Cs+ > K+> Na+ > Li+). Raising the temperatures from 25oC to physiological
37oC led to the largest conformational impact. For sulfate-based salts such as Li2SO4 and
MgSO4, both salts did not create large differences in the FLR intensities against their Cl-based counterpart (LiCl and MgCl2). This result suggests the decrease in FLR intensity is
associated with the cations whereas counterions (Cl- and SO 42-) did not have an effect
which is contrary to the MDC assay results where SO42--based salts generated higher
transglutaminase activity.
The greatest decreases in fluorescent emission spectral intensity occurred for FXIII A2 in
the presence of 100 mM Ca2+, a concentration that would fill all three FXIII calcium
binding sites. Furthermore, Ca2+ has a stronger affinity for the carbonyl group of peptide
amides than other cations (102). Binding of divalent Ca2+ is still considered the primary
driving force in causing significant conformational changes in FXIII both at low and high
mM calcium concentrations. A modest further decrease in maximum fluorescent intensity
could be promoted by including monovalent cations and working at a physiological
temperature. Control experiments confirmed that CsCl can serve as a quencher of Trp
fluorescence. However, the fluorescence effects are far less than those introduced by the
binding of up to 3 CaCl2 to intact FXIII. Binding of Ca2+ to generate FXIII A° exposes the
FXIII catalytic core which contains a majority of the Trp residues.
Molecular Dynamics simulations done by the group of Singh et al 2019 reported
that there is no drastic change in the overall structure of FXIII A2 when the concentration
of NaCl was raised from 150 mM to 1M (63). Increasing the NaCl concentration made the
FXIII electrostatic surface potential more positive but no large conformational changes
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were observed in this computational study (63). Using these results from the Biswas lab as
a guide, the following model can be developed. Divalent Ca2+ ions bind to FXIII-A at
distinct sites. The Ca2+ ions bind initially to Cab1 and later fill Cab2 and Cab3. X ray
crystal structures have shown that FXIII A2 in the presence of 40 mM CaCl2 and an active
site inhibitor undergoes a significant change in conformation that focuses on movemment
of FXIII β-barrels 1 and 2 that contributes to FXIII catalytic core domain exposure. The
Na+ ions (and other monovalent cations) must play additional supporting roles promoting
an electrostatic surface environment that helps maintain the active FXIII conformation.
The lower the Ca2+ concentration, the greater the contribution can be from monovalent
cations.
In summary, the fluorescence studies suggested that only the cationic species could
influence conformational properties detected by the FXIII Trp residues. The MDC
crosslinking studies revealed that the cations and anions could influence interactions with
its substrates and the resultant transglutaminase activity. With both experiment strategies,
the larger the cationic radii of the supportingt salts the greater the impact on FXIII function
and structure.
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CHAPTER III
CHARACTERIZING HUMAN FXIII WILD TYPE vs G262V

Introduction
FXIII and Transglutaminase 2 (TG2) are among the transglutaminases that exhibit
high structural similarity. These two enzymes share common structural domains including
β barrel 1 and 2, the catalytic core, and the β sandwich domain (113). FXIII is unique in
having an Activation Peptide (AP) segment that is cleaved by thrombin during the
activation process. Moreover, Ca2+ binding to FXIII promotes conversion from a dimer to
monomers. TG2 does not contain an AP segment, but its activation is regulated by a redox
reaction involving Ca2+, GTP, and thioredoxin (67). TG2 becomes inactive upon binding
GTP. In the presence of appropriate calcium concentrations, the GTP is released and TG2
becomes activated. In contrast to the zymogen FXIII A2 dimer, zymogen TG2 is a

Figure 28. Conformational changes of FXIII and TG2 upon activation. A) Activated monomeric
FXIII-Ao + bound inhibitor (PDB 4KYT B) TG2 activated + inhibitor trapped (fully extended)
conformation – PDB 2Q3Z).
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monomer (47). Both FXIII and TG2 expose their catalytic core domains during activation
by large movement of both the β barrels 1 and 2 (Fig. 28).
Human TG2 was sequenced and cloned in the early 1990s, and this sequence was
used in many published studies (114). When the TG2 was resequenced in 2014 (115), a
cloning error was discovered at the 224 position. The TG2 G224 should instead be a
Val224, (114,116). The natural variant exhibited an enhanced calcium binding affinity
thereby increasing transglutaminase activity. The sequences of FXIII (254-271) and TG2
(220-233) are highly conserved. An interesting exception is FXIII G262 located at the same
position as TG2 V224. This FXIII A structural position is situated within a helix near the
calcium binding Cab3 region, and TG2 has a highly conserved corresponding Cab3 region
(Fig. 29A). The primary goal of the study was to examine if FXIII G262V would exhibit
the same improvement in transglutaminase activity as TG2 G224V.

Figure 29. A) Sequence alignment of FXIII and TG2 showing G262 of FXIII

65

Materials
Mutagenesis of FXIII A2 Glycine 262 to Val262 (G262V) was performed using the
QuikChange II Site-Directed Mutagenesis kit (Agilent Tech, Santa Clara, CA) on
glutathione S-transferase (GST) tagged FXIII DNA serving as the template DNA. The
forward and reversed primers for the site-directed mutagenesis were synthesized by IDT
(Coralville, IA, USA). The FXIII A G262V Forward primer sequence was 5'- GTC AGC
CGT GTG GTG TCT GCA ATG GTG -3' whereas the reversed primer was 5'- CAC CAT
TGC AGA CAC CAC ACG GCT GAC -3' (Length: 27 bp, % GC: 59.26 % and melting
temp: 65.3 °C).
Bacteriological grade Tryptone, sodium dodecyl sulfate (SDS), KH2PO4 and
(NH4)2SO4 were purchased from VWR (OH, USA), BactoTM yeast extract (MD, USA),
EDTA from Fisher Bioreagents (NJ, USA), glycerol from MP Biomedicals (Ohio, USA),
glucose, lactose and ampicillin from Sigma (MO, USA). Deoxyribose nucleotide
triphosphate (DNTP), Phusion® High-Fidelity (PFQ) DNA polymerase by IDT
(Coralville, IA, USA). Gluthatione, RNAse, TritonX, leupeptin, aprotinin, benzamidine
HCl and streptomycin sulfate were from Calbiochem (Darmstadt, Germany), and the
lysozyme from Sigma (MO, USA).
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Methods
Site directed mutagenesis
A pGEX-6P-1 (Protein expression vector, GST-PrecissionTM protease), vector
system, provided by the Ariens and Philippou Labs of the University of Leeds, was used
as the vector for setting up the FXIII expression system. The FXIIIA has been inserted
downstream from the GST-tag sequence via the restriction sites BamH1 at the 5' position
and Sal1 at the 3'. The PGEX-6P-1 vector also provides resistance to ampicillin and other
related antibiotics since it encodes β lactamase (Fig. 30). Following expression and
purification, the GST is removed from the fusion protein by using the proteolytic enzyme
HRV3C that hydrolyzes the recognition sequence (Leu Glu Val Leu Phe Gln | Gly
Pro)(117).

Figure 30. A pGEX-6P-1 plasmid DNA map for FXIII A DNA. Left arrows shows the 5' and 3'
sequence primer and origin of replication is in green arrow (middle), AmpR gene encoding β
lactamase (blue), lac1 gene encoding lac repressor (yellow), GST-encoding sequence (blue
green). FXIIIA DNA is inserted downstream of the GST-sequence using Sal1 and BamH1
restriction sites (Created with BioRender).
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Mutagenesis of FXIII A2 G262V was performed using the QuikChange II SiteDirected Mutagenesis kit from Agilent Technologies, Santa Clara, CA. Following the
manufacturer’s protocol, the DNA template (20-50 ng) was mixed with the synthesized
forward and reverse DNA primers (120-150 ng), reaction buffer, DNA polymerase, and
dNTPs. This mixture was then run for 16 cycles in an Eppendorf 5332 PCR instrument.
For each PCR cycle, the parameters were: 30 sec at 95 °C for denaturation, 1 min at 55°C,
and 7 min at 68 °C for annealing. After completing the 16 cycles, the sample was chilled
for 2 min in the PCR instrument and transferred on ice for 30 minutes and subsequently
the restriction enzyme, Dpn1 was added. Since the DNA template was expressed in E. coli,
the DNA becomes methylated. Methylated DNA when used as the template in PCR will
produce non-methylated DNA. Upon introduction of restriction enzyme Dpn1, the original
methylated DNA will be digested and only the non-methylated DNA will be left. The tube
was then placed back in the PCR instrument for incubation at 37 oC for 1 h. The remaining
non-methylated DNA product was then transformed into E. coli XL-1 blue super competent
cells.
Transformation and Expression
Transformation was performed by placing the DNA product in a 42 oC water bath
for 45s. During transformation, supercompetent cells (E. coli XL-1) are capable of up
taking exogenous DNA (PCR product) which can eventually be used for downstream
application. After the 45s incubation, the sample was placed on ice for about 2 min. Next,
500 µL of preheated (42oC) Super Optimal Broth with Catabolite expression (SOC)
medium were added, mixed, and then incubated for 1 h at 37oC, 195 rpm. Using a ZYP
0.8G plates, 100 µL, 75 µL, and 50 µL of the transformed cells were streaked on the gel
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media. After incubation at 37oC for 16 hrs, a single colony was then selected and cultured
using a newly prepared LB broth containing 100 µg/mL ampicillin. The transformed E.
coli XL-1 was incubated in ZYP 0.8G non-inducing media overnight at 37oC. Cultured
cells were then harvested by centrifugation at 5000 rpm. The Qiagen Miniprep kitTM was
used for the plasmid DNA extraction, and the concentration was subsequently determined
using a Nanodrop spectrophotometer (Health Science Campus), University of Louisville.
The extracted DNA sample was then submitted for sequencing at the DNA Core facility of
the University of Louisville. After getting confirmation of the DNA sequence, the plasmid
vector was then subjected to transformation into E. coli BL21-Gold (DE3) competent cells
where ampicillin serves as the selection marker. The autoinduction protocol was then
utilized to perform the overexpression of FXIII A2 G262V variant using the same method
as described in Chapter 2 for Fbg αC (233-425).

Protein purification
The GST-tagged FXIII A2 G262V lysate underwent purification using GST-affinity
column chromatography on an AKTAprime chromatography system (GE Healthcare).
HRV3C protease was then added to cleave the GST tag by in-column digestion to obtain
the GST-free FXIII G262V. This purified FXIII G262V was then eluted with TBS buffer
containing 150 mM NaCl, 50 mM Tris acetate (pH 7.4) and its concentration was
determined spectrophotometrically (Agilent technologies, Cary 60 UV VIS) at 280 (Cary
WinUV version 5.0.0.999 program) nm using an extinction coefficient of 41480 M-1 cm-1
for FXIII G262V. Finally, the FXIII G262V fractions were run via SDS PAGE (4%
stacking gel and 8% resolving gel) to check for purity.
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Activation peptide cleavage of FXIII by rhIIa
Using activated recombinant human thrombin (rhIIa), the activation peptide (AP)
of FXIII A2 was cleaved off specifically at the R37-G38 peptide bond and released as a
4kDa AP (1-37) fragment. The progress of hydrolysis of the FXIII AP segment was
monitored by SDS-PAGE. The purpose for this experiment was to determine if mutation
of FXIII G262 to V262 would affect the rate of thrombin cleavage which is an important
step in proteolytic FXIII activation.
Initially, 9 tubes were prepared where one tube was intended for the zero point
(sample without rhIIa) and the 8 remaining other tubes contained 1 µL of 190 nM PPACK
that served to inhibit thrombin when the FXIIIA sample was mixed with it. The activation
mixture was prepared by mixing Tris acetate buffer, 2.2 µM FXIII A2, and 30 nM human
thrombin followed by incubation at 37oC. Next, 20 µL was removed at each time point (1,
2, 5, 10, 15, 30, 45, and 60 min) and added to the tube containing PPACK followed by
addition of 7 µL of 5X reducing buffer. The quenched samples were then boiled for 3 min
prior to gel loading. For each of the quenched samples, 20 µL were loaded into the SDS
PAGE gel wells (8% acrylamide of resolving gel and 4% acrylamide of stacking gel) and
run at 180 V for about 45 min. Finally, the gel was viewed under white light using a BioRad
GelDoc XR, and the saved image was used for quantification of how much FXIII zymogen
was left per unit time.
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MDC Assay: FXIII A2 WT and FXIII A2 G262V
Proteolytic activation
FXIII-A* was achieved by preparing the same total volume for activation (20µL)
and reaction mixture (160 µL) as used for the above mentioned FXIII activation studies.
The activation mixture was composed of 50 mM Tris acetate buffer saline, 2µM FXIII A2,
4 mM CaCl2, and 30 nM recombinant human thrombin (rhIIa). This mixture was then
incubated at 37 oC for 30 minutes. When the 30 min incubation period was reached, 1µL
of 1.9 mM PPACK was then added and mixed with the activation mixture to inhibit the
conversion of FXIII A2 to FXIII-A* via deactivation of rhIIa. When 8 µL FXIIIA* were
added to the reaction mixture, the final concentrations of the components were 4 mM
CaCl2, 5µM Fbg αC, 1 mM MDC, and 100 nM FXIII. The same procedure was taken for
quenching, loading, and viewing of gels as described in Chapter 2 (MDC assay). The series
of quenching time points included 1, 2, 3, 5, 10, 15, and 30 min.

Non-proteolytic activation
The MDC assay for the FXIIIA WT and mutant contained the same components
as described in Chapter 2 (MDC assay) except that the new time points (1, 2, 3, 5, 10, 15,
and 30 min) were used to compare FXIII-A* and FXIII-Ao.
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RESULTS
Monitoring the rate of Activation Peptide (AP) cleavage of FXIIIA WT vs FXIIIA G262V
Using thrombin (rhIIa), the activation peptide (AP) of the FXIII A2 WT and FXIII
G262V were cleaved at the Arg37-Gly38 peptide bond. Releasing these AP segments does
not activate FXIII A2 to FXIII-A* unless calcium is present to promote further
conformational changes to allow active site exposure. The ability of FXIII A2 to be
proteolytically activated depends on how readily the AP R37-G38 peptide bond is cleaved
by thrombin.

Figure 31. A) Crystal structure of FXIII-A showing the AP segments, G262 and the Cab3
residues B) SDS PAGE of FXIII AP-cleavage by thrombin as a function of time of FXIIIA
WT and FXIII G262V.

The SDS PAGE results showed thrombin fully cleaved the AP segment for WT and
mutant FXIII after 15–30-minute reaction times (Figure 31). The zero-time point
corresponds to the quenched sample containing FXIII-A (~83kDa) before thrombin was
added. The extent of AP cleavage could be monitored for the 1-60 min reaction period. A
new band at ~79 kDa increased in intensity as a function of reaction time that corresponded
to the loss of the FXIII (1-37) AP segment (4 kDa) following thrombin cleavage. The strong
similarities in the two-cleavage time point series imply that the mutation of G 262 to V262
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in FXIII does not affect the ability of thrombin to cleave the AP segment at FXIII R37G38.

MDC incorporation assay of FXIII-Ao WT vs FXIII-Ao G262V
The MDC crosslinking assay revealed that FXIII-Ao WT catalyzes a faster rate of MDC
incorporation into the Q-containing substrate Fbg αC than the FXIII-Ao G262V (Fig. 32).
However, by 30 min, both FXIII forms approached a similar crosslinking plateau (Fig
33D). These results suggest the G262V does not enhance nonproteolytic activation of FXIII
or transglutaminase activity. Instead, some hindrances in ability of FXIII G262V to
crosslink MDC into Fbg αC has occurred. This result suggests that mutation of Gly262 to
a larger hydrophobic Val262 creates a hindrance in the ability of FXIII-Ao to crosslink its
lysine substrate MDC into Fbg αC (233-425).

MDC incorporation assay of FXIII-A* WT vs FXIII-A* G262V
Proteolytically activated FXIII (FXIII-A*) forms were also evaluated to determine
the impact of the FXIII G262V variant (Fig. 33A and 33B). The concerted action of
thrombin-catalyzed AP cleavage and the presence of calcium makes the proteolytic
activation a more efficient mechanism than the nonproteolytic one. In the MDC
incorporation assay, results showed that there was no significant difference in the MDC
incorporation between the FXIII WT and its G262V variant (Fig. 33A and 33B). With
FXIII-A*, 4 mM CaCl2 can fill the main calcium binding site (Cab1) of FXIII and
subsequently, the other binding sites Cab2 and Cab3 are available to achieve full calcium
occupancy. However, kinetics data showed similar rates of plateau formation for FXIII WT
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and FXIII G262V which signifies that the mutation has no impact on the transglutaminase
activity of the FXIII-A* form (Fig 33D).
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Figure 33. A) Rate constant B) Plateau formation of FXIII WT and mutant.
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Discussion
The design of FXIII G262V was based on a TG2 mutation G224V which led to
increased calcium binding and transglutaminase activity (116,118). The crystal structures
of FXIII and TG2 indicate (Fig. 31) that FXIII Gly262 and the TG2 Gly224 both are located
within an α helix that connects to a Ca2+ binding loop in the catalytic core domain (52,119).
In the nonproteolytically activated FXIII-Ao crystal structure (PDB 4KTY), the Cab3 loop
utilizes Ala264, Asn267, K269, Asp270, and Asp271 to bind calcium. In the TG2 loop
(Fig. 34), Asp232 and Asp233 correspond to FXIII Asp270 and Asp271 which are part of
the calcium binding site 3. With TG2, the Cab3 sequence serves as the main calcium
binding site whereas with FXIII, Cab1 is actually the primary calcium binding site while
Cab2 and Cab3 play additional roles.
The purified FXIII G262V variant was first evaluated for its response to thrombin
cleavage of AP fragment. This N-terminal 37 amino acid segment Ala1-Gly37 (4 kDa) of
FXIII is connected to the β sandwich. A review of FXIII A2 structure reveals that the AP
segment binds not only to its own catalytic core domain but also straddles across the dimer
interface to interact with the other dimer partner (Fig. 35A). For the activation peptide
cleavage assay times, both the FXIII-A WT and the mutant FXIII-A G262V could become
completely free of the AP fragment by 30 min as seen by the expected 4 kDa decrease in
molecular weight (Fig. 34B). This result suggests that the G262V mutation did not affect
thrombin cleavage of the AP fragments. FXIII residues Phe8-Arg15 of AP make
interactions with the other FXIII subunit. The Arg11 and Arg12 of the AP segment form
salt bridge interactions with Asp343, one of the residues directly bound to Cab2, whereas
the remaining residues in Phe8-Arg15 only form hydrogen bonds. The absence of Ca2+ in
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the SDS PAGE based cleavage assay means that AP hydrolysis can be monitored, but no
enzymatic activity can be induced.

FXIII Cab3 region

TG2 Cab3 equivalent region
Figure 34. FXIII-A Calcium binding site 3 (PDB 4KTY) and TG2 major
calcium binding region (FXIII Cab3 equivalent, PDB 2Q3Z)

Using proteolytically activated FXIII-A*, the MDC incorporation assays revealed,
no significant difference between the transglutaminase activities of FXIII WT and FXIII
G262V. Both WT and mutant FXIII-A* generated the same high rates of crosslinking with
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the plateaus reached by 5 min. The FXIII-A* G262V mutation in the α helix could have
caused changes in the noncovalent interactions of helical residues near Val262, but they
did not impact the transglutaminase activity of proteolytically activated FXIII. This form
of FXIII relies on Ca2+ binding to Cab1 to promote transglutaminase activity.
Under nonproteolytic activation conditions involving 100 mM CaCl2, the FXIII-Ao
G262V variant exhibited a slower rate of achieving transglutaminase activity than the
FXIII-Ao WT. At 100 mM, this Ca2+ concentration is predicted to bind Cab1, Cab2, and
Cab3. In the crystal structure of FXIII (4KTY), the FXIII-A G262 position does not have
direct interaction with the Cab3 binding loop (Fig. 34). Instead G262 participates in a
hydrogen bonding network that links G262, Val226, Leu275, and Ala268. Both Ala268
and Leu275 are within the Cab3 loop (Fig. 34). The G262V mutation introduces a more
hydrophobic residue that may have promoted long-ranged instability in the Cab3 region.
This structural review suggests the G262V mutant may have impacted calcium binding at
Cab3 and influenced FXIII activity. In a previous study conducted by Souri et al 2014,
another known Gly mutation (G273V) within the Cab3 region was detected in patients with
severe congenital FXIII deficiency (120). The FXIII variant G273V has also been reported
to promote instability and this Gly is positioned within the Cab3 binding loop. Directly
altering the Ca2+ binding site may have had a greater effect than FXIII G262V impacting
the neighboring α helix.
Furthermore, a study by Li et al 2020 revealed that Arg260 and Lys257 within the
Cab3 region are considered essential residues for promoting FXIII core domain-core
domain interactions along the FXIII A2 dimer interface (121). Arg260 and Lys257 are both
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within the α helix where the Gly262 is also positioned. The G262V variant may have
further impacted interactions in the proximity of Arg260 and Ly257.

Figure 35. FXIII A2 spatial views showing the residues in Cab1 (sky blue), Cab2 (pink)
and Cab3 (green). The AP peptide (blue and red) are from two FXIII-A subunits. a)
shows the FXIII A2 front view, b) FXIII A2 view flipped vertically backward at 90o c)
FXIII A2 view flipped counterclockwise at 90o.
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Figure 35 shows the structure of zymogen FXIII A2 in different spatial orientations.
At the dimer interface, where most of the subunit interactions occur, the AP segment
segments of both A subunits and the Cab3 residues are the most exposed for solvent or
ionic interactions (Fig 35B and 35C). Cab2 residues are positioned in the middle and Cab
1 at the bottom. Fig. 35A also reveals that among the Cab sites, the two Cab3 positions are
positioned in close proximity along the A2 dimer interface. By contrast, individual Cab1Cab1 and Cab2-Cab2 sets are each located at opposite positions along the dimer interface.
Since nonproteolytic activation benefits from high Ca2+ concentrations to promote
filling of all Cab sites, the G262V variant has slightly affected binding at Cab3 which
resulted in a decrease in FXIII activity. This impact on calcium binding could be overcome
when the mutant was activated proteolytically. There was no significant difference in the
transglutaminase activity between the FXIII WT and G262V mutant when tested following
proteolytic activation. The low mM Ca2+ would primarily target Cab1. In the previous AUC
studies performed by Anokhin et al (60), FXIII-A* WT was demonstrated to be more
conformationally flexible than FXIII-Ao and served as a better transglutaminase for
promoting MDC crosslinking to FbgαC.
The contrasting results of FXIII-Ao vs FXIII-A* suggest that upon thrombin
cleavage, the instability caused by the G262V variant is overcome in proteolytic activation
since the FXIII A2 to FXIII-A* formation is an AP-cleavage driven activation and reliant
on low mM calcium concentration levels. FXIII-A* G262V is predicted to be more driven
by calcium binding to Cab1 than Cab3. Meanwhile, nonproteolytically activated FXIII A2
to FXIII-Ao, is a calcium-driven activation and instability within Cab3 would impact FXIII
activation and activity. The sequences surrounding FXIII G262V or TG2 G224V have
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highly conserved residues, but the mode of activation of TG2 and FXIII are different. The
main calcium binding site of FXIII is Cab1(63) whereas that of TG2 is Cab3 (122) although
they are positioned in the same location in catalytic core domain. The sequences of the
TG2 main calcium binding site have high similarity to the Cab3 region of FXIII. In future
research studies, other residues within the Cab3 region that are involved in binding of Ca2+
and the lysine-containing substrate could be further investigated for effects on
transglutaminase activity.
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Summary and Conclusion
This MS Thesis project explored the effects of monovalent/divalent cations and
their accompanying anions on the transglutaminase activity and conformational properties
of Factor XIII. For the various studies, FXIII was activated non-proteolytically in the
presence of elevated levels of Ca2+ (2 mM – 100 mM) or proteolytically by thrombincatalyzed cleavage of the Activation Peptide in the presence of 4 mM Ca2+.
Studies in Chapter 2 utilized fluorescent mondansylcadaverine SDS-PAGE
crosslinking assays to examine the effects of ionic radius and ionic strength on promoting
FXIII-A activity. FXIII A2 was activated in the presence of 4 mM CaCl2 and different
concentrations of monovalent salts. Increasing concentrations of NaCl or KCl (150 mM –
500 mM) generated an increase in transglutaminase activity. Group 1 cations (Cl--based
salts) at 350 mM showed increased MDC incorporation as a function of ionic radius in the
order Cs+> K+ >Na+> Li+. When sulfate-based salts were compared with chloride-based
salts such as LiCl vs Li2SO4 or MgCl2 vs MgSO4, the higher ionic strength properties of
the sulfates contributed to further increases in transglutaminase activity. Chapter 2 studies
demonstrated that for monovalent ions, increasing ionic strengths or ionic radius promoted
increased transglutaminase activity.
Studies in Chapter 3 focused on using intrinsic fluorescence to monitor for changes
in FXIII conformation in the presence of divalent Ca2+ and the monovalent cation series.
FXIII contains 15 Tryptophan residues that can become further exposed to solvent upon
FXIII activation. In the presence the cations, decreases in fluorescence corresponding to
increases in protein polarity could be detected. Binding of Ca2+ was found to be the main
driver of the conformational changes detected to FXIII. The monovalent cations provided
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additional supporting roles with their effects again tied with ionic radius (Cs+ > K+ > Na+>
Li+).
Studies in Chapter 4 involved determining whether the ability to nonproteolytically
activate FXIII could be enhanced by introducing a G262V mutation from TG2 into the
Cab3 calcium binding site. This mutation caused a hindrance in the ability of Ca2+ to bind
at Cab3 resulting in a decrease in transglutaminase activity. The same mutation, however,
did not alter proteolytic activation nor impact its transglutaminase activity. Mutation at the
Cab3 region influenced nonproteolytic activation which is calcium driven, but this impact
on Cab3 was overcome proteolytically which is considered a more thrombin-driven
activation.
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Supplemental Figure S1. Site directed mutagenesis purification results for
FXIII-A G262V generation. A) Elution profile of FXIII-A mutant B) Lane 1
– Molecular weight marker, Lane 2 – Lysate, Lane 3 – load flow-through,
Lane 4 – washed flow-through, Lane 5- washed flow-through, Lane 6- GSTPSP, Lane 7 – FXIII-A fraction A, C) Lane 2 – FXIII-A fraction B, Lane 3,4Glutathione eluted fractions.
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Supporting Table S1. Curved fit and Bar Graph data (30 min reaction time) of MDC
incorporation assay (Chapter 2 and 4)
FLR intensity
(30 min reaction
time)

Emax (Plateau)

Initial reaction rate
K (s-1)

0.008±0.000
0.024±0.002
0.037±0.004
0.057±0.004

0.071
0.090
0.059
0.112

0.004
0.010
0.033
0.025

0.018±0.001
0.038±0.003
0.057±0.002

Unstable
0.101
0.064

0.00
0.015
0.084

0.016±0.002

0.031

0.025

350 mM
CsCl
350 mM
TMAC
350 mM
ChCl
350 mM
MgCl2

0.057±0.002

0.113

0.023

0.052±0.002

0.088

0.029

0.030±0.002

0.093

0.013

0.014±0.001

Unstable

0.00

350 mM
MgSO4

0.025±0.003

0.101

0.048

350 mM
FXIIIA* WT
FXIIIA* G262V
FXIIIAo WT
FXIIIAo G262V

0.077±0.001
0.069±0.001
0.051±0.004
0.063±0.000
0.063±0.003

0.046
0.058
0.056
0.076
0.067

0.923
0.607
0.799
0.178
0.113

NaCl
150 mM
350 mM
415 mM
500 mM
KCl
150 mM
350 mM
500 mM
LiCl
350 mM
Li2SO4

Data for normalized in-gel fluorescence intensities via MDC incorporation assay were plotted
using One-phase association GraphPad prism 9.2.0 software. The equation used was Y=Yo +
(Plateau-Yo)x(1-exp(-Kx)) where Y represents the normalized in-gel fluorescence intensity
with β-CaseinXMDC as a positive control, Yo is the sample at zero time point (quenched
FXIII-A2 before reaction), K as the rate constant in min-1, Plateau or Emax (Y value at infinite
time), and t as time in minutes.
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Supporting Table S2. Percent change in terms Maximum fluorescence intensity of FXIII
under different ionic and temperature conditions (Chapter 3)
FXIIIA2 plus
ions

% drop
against
FXIII
(RT)

% drop
against
FXIII
(37oC)

FXIIIA2 plus
ions

% drop
against
FXIII (RT)

% drop
against FXIII
(37oC)

350 mM LiCl +
4 mM CaCl2

19

34

4 mM CaCl2

20

44

150 mM NaCl

24

25

100 mM CaCl2

44

66

350 mM NaCl
+ 4 mM CaCl2

30

43

350 mM
MgCl2+ 4 mM
CaCl2

29

38

350 mM KCl +
4 mM CaCl2

29

45

350 mM
MgSO4+ 4 mM
CaCl2

29

40

350 mM CsCl
+ 4 mM CaCl2

42

49

350 mM
Li2SO4+ 4 mM
CaCl2

24

33

Trp fluorescence data were analyzed using GraphPad 9.2.0 software to determine the maximum
intensity (a.u). Percent decrease in terms maximum intensity using the emission spectra results
were compared with the generated maximum intensity of FXIII-A2 in borate solution at room
temperature and 37oC, physiological temperature.
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